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CHAPTER I
Introduction
Recurrent events are a common outcome of interest in many clinical applications,
and are often used to evaluate new treatments. Many important clinical outcomes
related not only to morbidity but also healthcare costs can occur repeatedly, and
analysis of recurrent event rates allows for the estimation of treatment effects on
these types of outcomes. Common examples of recurrent events include repeat in-
fections, myocardial infarctions, and complications related to medical procedures as
well as resource utilization outcomes like hospitalizations and medical costs. How-
ever, when treatment initiation occurs after the start of follow-up existing methods
for the analysis of recurrent events are generally inapplicable or yield treatment ef-
fect parameters with unsatisfactory interpretations. In this dissertation we propose
methodology that evaluates the effect of time-dependent treatments on multivariate
survival outcomes.
In Chapter II we consider a time-dependent treatment that is relatively rare,
and develop a two-stage method of estimating the effect of this treatment on the
recurrent event rate. Since treatment is initiated after the start of follow-up the
ideal comparison is between a subject that receives treatment at time s and the
same subject under the scenario where the treatment does not exist. Since the
1
2counterfactual absence-of-treatment experience is not observable in practice, our goal
is to use other “similar” subjects to mimic this counterfactual experience. We identify
these subjects by using a conditional prognostic model (i.e., conditional on previous
events and any other relevant history) to find subjects with similar pre-treatment
trajectories. Subjects that remain untreated at time s are then matched to the
subject treated at time s if their prognostic score is within a given distance from
the score of the treated subject. We then use the sequential stratification method
(Schaubel et al, 2009) to estimate the effect of treatment on the recurrent event rate
with each set of treated subjects and matched controls serving as a stratum in the
analysis. The method conditions on the history up until the time of treatment (s),
but is marginal beyond s. Note that matched subjects who are subsequently treated
are censored from stratum where they serve as controls. While this generally results
in dependent censoring, with a rare treatment, estimates remain unbiased. We seek
to identify the threshold above which the dependent censoring results in bias.
In Chapter III we extend this method in two important directions. First, treat-
ment is no longer assumed to be rare. Second, multiple treatments are available. In
particular, we consider the case where there is both a “standard” and an “experi-
mental” treatment. In this scenario all subjects begin follow-up untreated, some go
on to receive standard treatment, others go on to receive the experimental treat-
ment, and still others remain untreated. Our objective is to compare the recurrent
event rates under experimental treatment and “conventional therapy”; i.e., beginning
follow-up untreated and remaining in that state or subsequently receiving standard
treatment. In this setting, subjects serving as matched controls are censored if they
receive experimental treatment, but remain in the comparison group if they go on
to receive standard treatment. We also assume that the experimental treatment is
3more common, i.e. it exceeds the threshold determined in Chapter II that results
in bias due to dependent censoring. To account for this we use a variant of Inverse
Probability of Censoring Weighting (IPCW, Robins and Rotnitzky, 1992, Robins and
Finkelstein, 2000). We model the hazard of experimental treatment using traditional
proportional hazards methods adjusting for relevant covariates and history, and use
this to construct weights representing the hazard of experimental treatment between
time s and s + t. Sequential stratification methods are then used to determine the
effect of experimental treatment on the recurrent event rate.
In Chapter IV we return to the scenario where there is only one treatment but
remove the assumption that the treatment is rare. In this chapter we develop a
method for estimating the effect of a time-dependent treatment on correlated recur-
rent event and survival outcomes. Here we assume that there is a latent process
(unobserved random effect) related to both the recurrent and terminal events, and
that the terminal event stops all subsequent observations of the recurrent event.
Under this scenario we propose to jointly model the pre-treatment recurrent and
terminal events using a frailty model in order to estimate the treatment-free trajec-
tories for both event types as well as the subject-specific frailties. The matching of
treated subjects then proceeds using the estimated intensities and hazards as well as
the frailties. The final estimates of the treatment effect on the recurrent event rate
and terminal event hazard are estimated separately using sequential stratification
and the weighting method described in Chapter III.
The methods described above are applied to data from the Adult-to-Adult Liv-
ing Donor Liver Transplantation Cohort Study (A2ALL). A2ALL is a multicenter
NIH-funded cohort studying morbidity and mortality related to living donor liver
transplant (LDLT) for both donors and recipients. The study collected both ret-
4rospective and prospective data on potential LDLT recipients transplanted between
1998 and 2014. Data collection included demographic and clinical information related
to recipient’s liver disease and health status at donor evaluation, intraoperative in-
formation, vital status and laboratory values at specified time points post-donation,
as well as information on complications and hospitalizations. Data collection began
at the time of donor evaluation; some potential recipients went on to receive an
LDLT, some received a deceased donor transplant (DDLT), and others remained on
the waitlist.
CHAPTER II
Estimating the effect of a rare time-dependent treatment on
the recurrent event rate
2.1 Introduction
Recurrent events often serve as the basis for measuring treatment effects in ob-
servational studies. A reduction in outcomes, such as repeated myocardial infarction
or opportunistic infections, indicates that a treatment has a positive effect on mor-
bidity. Reductions in hospital admission rates among the treatment group would
imply that lower morbidity as well as reduced health care costs are associated with
(or caused by) treatment.
Methods for analyzing recurrent events have been well described in the literature.
Models have been developed that condition on the event history (Anderson and Gill,
1982) or previous number of events (Pepe and Cai, 1993). Marginal models, such as
those of Lawless and Nadeau (1995) or Lin et al. (2000), allow for an interpretation
of covariate effects on the recurrent event rate that does not require patients to have
similar event histories. Few papers to date have explored methods for using recurrent
events as an evaluation of an experimental treatment, with exceptions being Cook
et al. (2009) and Schaubel and Zhang (2010).
Treatment can be initiated after the beginning of follow-up, which occurs fre-
quently in studies without randomization. While some existing recurrent event
5
6methods can incorporate time-dependent covariates (Chen et al, 2013), these tra-
ditional methods often do not give interpretations that satisfy the research question
of interest. In the settings often of interest, treatment initiation depends on inter-
nal processes such as disease progression or the event history itself, violating the
assumption of most time-dependent recurrent event methods that time-dependent
covariates be external (Kalbfleisch and Prentice, 2002). Ideally, we would begin
follow-up of an untreated patient, and after treatment initiation we would compare
the recurrent event rate to that of the same patient had they remained untreated.
This counterfactual experience is unobservable in practice, however.
In an attempt to compare each treated subject with their unobservable counterfac-
tual treatment-free experience, this chapter will extend the sequential stratification
method described by Schaubel et al. (2009) to the recurrent event setting. For every
subject treated at time s, subjects that are eligible to receive treatment at time s but
do not are matched to the treated subject. Each treated subjects’s post-treatment
recurrent event rate is compared to the averaged matched recurrent event rate in
what can be conceptualized as a subject-level experiment. Matched subjects that
subsequently receive treatment are censored from experiments for which they serve
as controls, and begin their own experiment as the treated subject. Note that,in
every experiment, the comparison of interest begins at time s, such that recurrent
events that occur in [0, s) are not considered.
Schaubel et al (2009) proposed combining hard covariate matching and adjustment
to ensure that matched subjects were ‘similar’ to the treated subject in addition to
the requirement that they remain untreated at time s. This method was proposed in
the univariate survival setting where failure times prior to treatment are not observed
for treated subjects. However, information regarding pre-treatment recurrent event
7trajectories are available on all subjects in the setting described above. Given that
event history is a strong predictor of the recurrent event rate, we propose to leverage
this information using a two-stage modeling approach. In the first stage, we use a
conditional rate model to describe pre-treatment event trajectories for all subjects.
We then use the linear predictor from this first stage model to caliper-match as yet
untreated patients to those receiving treatment at time s. The goal is to create a
control group with an event trajectory similar to that which the treated patient would
have experienced had treatment not been available. The final model for the recurrent
event rate includes only the treatment effect and a measure of distance between the
prognostic score of the treated subject and that of the matched controls.
The method proposed is not restricted to “treatment”’ in the classical sense, and
is in fact applicable to any state change. Often this state change is in the form of
treatment such as initiation of new medication or performance of a procedure, but
this is not always the case. Diagnosis of disease or experience of a medical event such
as injury could constitute a state change for which comparing the recurrent event
rate in the presence and absence of the state change is of clinical or policy interest.
This will be discussed further in relation to the application of the method to liver
transplantation.
The remainder of this chapter proceeds as follows. In Section 2.2 we introduce
the notation and proposed models and describe the parameter estimation. Section
2.3 presents results of simulation studies to demonstrate the performance of the
treatment effect estimator in moderate sized samples. An application to living donor
liver transplant is described in Section 2.4 using data from the Adult-to-Adult Living
Donor Liver Transplantation Cohort Study (A2ALL). Some concluding remarks are
offered in Section 2.5.
82.2 Methods
2.2.1 Notation
In the following, i represents subject (i = 1, . . . , n), Ti is treatment time, with
Ti ≥ 0, and Z∗i (t) represents the time-dependent covariate for subject i. We assume
for the purposes of this chapter that subjects treated at time Ti remain treated
for the duration of follow-up. The true number of events for subject i in [0, t] is
defined as N∗i (t) =
∫ t
0
dN∗i (u). Event and treatment times are subject to independent
right censoring by Ci, assumed to be administrative in this setting without loss of
generality. The number of observed events is given by Ni(t) =
∫ t
0
I(Ci > u) dN
∗
i (u).
The number of pre-treatment events in (0, t] is given by the counting process
N0i (t) =
∫ t
0
I(Ti > u) dN
∗
i (u).(2.1)
If patient i receives treatment at time s; i.e., Ti = s, then the post-treatment event
counter is defined as
N?i (t; s) = I(Ti = s)
∫ s+t
s
dN∗i (u).(2.2)
Note that it will be our convention that N(t; s) refers to the interval of length t, but
starting at time s; a single time index, as in the previously-defined N0i (t), pertains to
the (0, t] time interval. Correspondingly, we define an event counter representing the
events that would have been experienced in the absence of treatment, also beginning
at time s,
N0i (t; s) =
∫ s+t
s
I(Ti > u)dN
∗
i (u).(2.3)
Note that (2.3) is the pre-treatment event counter described in (2.1) but instead of
(0, t] the counter N0i (t; s) tracks the patient on (s, s + t]. For a subject eligible to
receive the treatment at time s, (i.e. I(Ti ≥ s)), if Ti = s, the counting process (2.2)
9takes effect; if the treatment had not been available, process (2.3) takes effect. The
subject is untreated on (0, s) under either scenario to which (2.2) and (2.3) pertain.
Finally, we define a 0/1 process for being observed to receive treatment,
NTi (t) =
∫ t
0
I(Ci > u)dI(Ti ≤ u).(2.4)
2.2.2 Proposed Models
As described above, the goal of this method is to compare the post-treatment
recurrent event mean to the corresponding event mean under no treatment. We
denote the mean of (2.2) by
µ?i (t; s) = E
[∫ t
0
N?i (du; s)|Ti = s,H i(s)
]
,(2.5)
where H i(s) = {Z∗i (u), Ni(u), I(Ti > u), I(Ci > u); 0 ≤ u < s} represents the
observed pre-treatment history for subject i on [0, s).
Similarly, in the absence of treatment, the mean of (2.3) can be written as
µ0i (t; s) = E
[∫ t
0
N0i (du; s)|H i(s), Ti > u
]
.(2.6)
Note, both models are partly conditional (Pepe and Couper, 1997, Zheng and
Heagerty 2005, Gong and Schaubel 2013) in the sense that they condition on the
history up until time s as opposed to s + t. We do not model either (2.5) or (2.6)
directly, instead, our model of interest is given by
µ?i (t; s) = µ
0
i (t; s) exp{β?},(2.7)
which can equivalently be expressed in terms of a rate function by
µ?i (dt; s) = µ
0
i (dt; s) exp{β?}.(2.8)
In this model µ0i (t; s), the treatment-free mean number of events is scaled up or down
by exp{β?} if subject i received the experimental treatment at time s. The mean
10
number of post-treatment events is then compared to the mean number of treatment-
free events after time s. It is conceivable that the treatment effect could depend on
time since treatment, t, or time of treatment, s, and this model can be extended to
accommodate a time-dependent β? in the form β?(t; ·), β?(·; s) or β?(t; s). Note that
these different time-dependent forms of β? could be any parametric function of time
such as linear or log-linear; time could also be categorized to examine the functional
form of the time-dependent effect.
Since we cannot observe a patients’ pre-treatment experience once treatment is
initiated, a patient treated at time s will be compared to similar patients who did not
start treatment at follow-up time s but were eligible to do so. Similar to Schaubel et
al. (2009), we use the concept that each treatment time initiates an “experiment”,
in which the recipient of the treatment is compared to ‘similar’ treatment-eligible
candidates. Note that ‘similar’, in this context, refers to current status (i.e., at time
s) and history on [0, s). Eligibility for the comparison is defined as
ei(s) = I(Ti = s) + I(Ti > s),
i.e., at time s, patient i either received the treatment or remained untreated.
Our method of estimating β? from (2.8) involves a stratified analysis. Each treated
patient generates a stratum, which will include the index patient as well as similar
treatment-eligible patients. Here we define similar as both treatment eligible at s,
ei(s), and similar with regard to accumulated covariate and recurrent event history
on (0, s], H i(s). In order to quantify each subject’s history, we use a prognostic
score (Hansen, 2008) based on the pre-treatment event rate, modeled using a time-
dependent proportional rates model,
11
dµ0i (t) = E [dN
∗
i (t)|H i(t), Ti > t] = exp{αT0Zi(t)}dµ0(t),(2.9)
where the covariate Zi(t) is chosen to capture the pertinent components of the his-
tory, E[dN∗i (t)|H i(t), Ti > t] = E[dN∗i (t)|Zi(t), Ti > t]. Model (2.9) resembles the
marginal Lin et al. (2000) model, but is more accurately interpreted as the condi-
tional Andersen-Gill (1982) model, due to the explicit dependence on the prior event
history, a property avoided by Lin et al. (2000). The regression parameter α0 from
(2.9) can be computed by solving the unweighted Cox (1975) score equation. Due to
the dependence on internal covariates (Kalbfleisch and Prentice, 2002), elements of
α0 are difficult to interpret. However, the purpose of this model is matching similar
subjects on [0, s), not interpretation.
The purpose of the prognostic score is to match patients that have similar pre-
treatment event rates, the rationale being that previous event rate is the most im-
portant predictor of the current event rate. Unlike a propensity score, which uses the
treatment event rate to match subjects with similar probabilities of being treated,
the prognostic score aims to compare the effect of treatment on the event rate among
subjects that were on the same trajectory with respect to their pre-treatment event
rate. The use of prognostic scores in conjunction with, or as an alternative to,
propensity scores has been considered in several reports (Rubin and Thomas, 2000,
Stuart, Lee, and Leacy, 2013, Leacy and Stuart, 2014, Li, Schaubel, and He, 2014)
and will be discussed later. Once the prognostic scores have been estimated, caliper
matching is used to assign untreated control subjects to a subject receiving treatment
at time s. Caliper matching requires that the prognostic scores of matched subjects
be within a certain radius of the prognostic score of the index subject. Appropriate
selection of the caliper involves balancing the need for homogeneity within-stratum
12
with the need to have an adequate number of matches for each index subject. The
discrepancy between prognostic scores for experimental subject j and control subject
i can be quantified through the subject-pair specific rate ratio,
ψi,j(s) =
dµ0i (s)
dµ0j(s)
= exp{αT0 [Zi(s)−Zj(s)]}.
Subject i is ‘similar’ on [0, s) to subject j if | logψij(s)| ≤ , where  > 0 is a
pre-determined constant.
Combining the eligibility indicators and prognostic scores, patient i is included in
the stratum generated by patient j if mij(s) = 1, where
mij(s) = ei(s)I(Ti > s)ej(s)I(Tj = s)I(| log ψ̂ij(s)| ≤ ),
with ψ̂ij(s) = exp{α̂T0 [Zi(s)−Zj(s)]}. In order to account for the residual difference
between patients i and j, we propose to adjust for log ψ̂ij(s) in the final model.
Incorporating the eligibility indicator and the prognostic score distance, the final
fitted model for the event mean for stratum j is then
µ?ij(t; s) = mij(s)µ
0
i (t; s) exp{β?I(Ti = s) + βψ log ψ̂ij(s)}.(2.10)
In (2.10), j is the stratum (generated by patient j through Tj = s) and i is the
patient within stratum. The model governs the treated patient through the indicator
I(Ti = s), which equals 1 if i = j. The vector of parameters to be estimated and the
corresponding covariates are given by
β?ψ =
 β?
βψ
 Z?i (s) =
 I(Ti = s)
log ψ̂ij(s)
 ,(2.11)
such that model (2.10) can be re-written as µ?i (t; s) = mij(s)µ
0
i (t; s) exp{βT?ψZ?i (s)}.
Subjects matched to the treated subject enter the experiment without receiving
any treatment, but could subsequently receive treatment. If a matched subject re-
ceives treatment after time s they are censored from all experiments in which they
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serve as controls and begin their own experiment as the index subject. This generally
results in dependent censoring since, although treatment can be considered random
given H i(s+t), the model for µ
?
ij(t; s) from (2.10) only conditions on H i(s), the pre-
treatment history up to time s. While this could be addressed though Inverse Prob-
ability of Censoring Weighting (IPCW, Robins and Finkelstein, 2000, Miloslavsky et
al, 2004, Smith and Schaubel, 2015), in this chapter we consider treatments that are
relatively rare, with rates small enough such that bias due to dependent censoring
is negligible. Section 3 will investigate through simulation treatment rates at which
dependent censoring needs to be addressed.
2.2.3 Parameter Estimation
In order to estimate β? we define the pertinent risk set indicator for stratum j,
Yij(t; s) = mij(s)I(Ci > s+ t){I(Ti = s) + I(Ti > s+ t)}.
If, given H i(s) matched subjects are randomly assigned to treatment after time s,
the process
mij(s)
∫ τ−s
0
Mij(du; s),(2.12)
wheremij(s) is the matching indicator described above, Mij(du; s) = Yij(u; s){Ni(du; s)−
µij(du; s)}, and τ is chosen to satisfy P (Ci ≥ τ) > 0 and often set to max{C1, . . . , Cn},
would have mean zero. As mentioned above, bias due to censoring of subsequently
treated controls is expected to be minimal in the setting of rare treatment, so we
assume the condition above holds.
Aggregating across subjects for the experiment occurring at time s produces the
set of zero mean processes,
∑n
i=1mij(s)
∫ t
0
Mij(du; s)(2.13)
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and
∑n
i=1mij(s)
∫ t
0
Z?i (s)Mij(du; s).(2.14)
We reorganize this system to solve implicitly for the baseline mean, µ00(u; s) in (2.13),
then substitute into (2.14). Then, aggregating across all experiments yields the final
estimating function for β?ψ,
U(β) =
n∑
j=1
n∑
i=1
∫ τ
0
mij(s)
∫ τ−s
0
{Z?i (s)−Z?(u; s)}Ni(du; s)dNTj (s),(2.15)
where
Z?(u; s) =
∑n
`=1 Y`j(u; s)Z
?
`(s) exp{βT?ψZ?`(s)}∑n
`=1 Y`j(u; s) exp{βT?ψZ?`(s)}
.(2.16)
Since U(β) from (2.15) behaves asymptotically like a zero-mean estimating function,
the solution to U(β) = 0, denoted by β̂?ψ, should yield a consistent estimator of
β?ψ.
2.2.4 Asymptotic Properties
To proceed with inference on β̂ we need to estimate the variance of β̂. To do this
we first explore the distribution of n1/2(β̂ − β) as n → ∞. Using results initially
derived by Lin et al (2000) it can be shown that
n1/2(β̂ − β) = A−1(β)n−1/2
n∑
i=1
Ui(β) + op(1),(2.17)
where
U(β) =
n∑
j=1
n∑
i=1
∫ τ
0
mij(s)
∫ τ−s
0
{Z?i (s)−Z?(u; s)}Ni(du; s)dNTj (s)
as above and A(β) is the limiting value of the second derivative matrix, given by
Â(β) = n−1
n∑
j=1
n∑
i=1
∫ τ
0
mij(s)
∫ τ−s
0
{Z?i (s)−Z?(u; s)}⊗2Ni(du; s) dNTj (s).
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Note that in order to show (2.17) above it must be shown that (2.15) has mean
zero. To do this we first rewrite the interior integral as from (2.15) as
n∑
i=1
∫ τ−s
0
{Z?i (s)−Z?(u; s)}Mi(du; s),(2.18)
where Mi(t; s) is defined as above. Since (2.10) is not the intensity model of Anderson
and Gill (1982) but a proportional rates model similar to Lin et al (2000), the Mi(t; s)
are not martingales and therefore the martingale central limit theorem does not apply.
However, E{dMi(t; s)|Z?(u; s)} = 0 in the setting described above given
Mi(dt; s) = Yi(t; s)[Ni(dt; s)− µ0i (dt; s) exp{βT?ψZ?i (s)}]
and therefore (2.18) has mean zero under the assumed model. It follows that
1
n
n∑
j=1
n∑
i=1
∫ τ
0
∫ τ−s
0
{Z?i (s)− z?(u; s)}Mi(du; s)dNTj (u)
also has mean zero because {Z?i (s)−z?(u; s)}Mi(du; s) and dNTj (t) are independent
when i 6= j and when i = j dNTj (t) = 1 is embedded in the covariate Z?i (s).
It can be shown through empirical process theory (Shorack and Wellner, 1986,
Karatzas and Shreve, 1988, Pollard, 1990, Bilias et al 1997) that n−1/2U(β) converges
weakly to a zero mean Gaussian process under certain regularity conditions such as
those listed in Lin et al (2000). Further, by the Weak Law of Large Numbers,
the matrix Â(β) converges in probability to A(β). Then, by applying Slutsky’s
Theorem, (2.17) converges to a normal distribution with mean zero and variance
A−1(β)B(β)A−1(β), where B(β) = E[Ui(β)UTi (β)]. The form of the variance of
(2.17) suggests the robust sandwich estimator with Â(β) as given above and B(β)
estimated by B̂(β) where
B̂(β) =
1
n
n∑
i=1
Ûi(β)
⊗2
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with
Ûi(β) =
n∑
j=1
n∑
i=1
∫ τ
0
mij(s)
∫ τ−s
0
{Z?i (s)−Z?(u; s)}M̂i(du; s)dNTj (s).
2.2.5 Variance Estimation
The variance of β can be estimated via the robust sandwich estimator. This
was used for several reasons. First, recurrent events are clustered within subject,
and therefore observed events are not independent. Second, subjects can serve as
controls in multiple strata, i.e., the data set for the final model may include repeated
instances of a subject’s recurrent event experience. The performance of this robust
sandwich estimator will be tested through simulation.
2.3 Simulation Study
2.3.1 Simulations of Proposed Method
We conducted simulations to demonstrate the properties of the proposed estimator
in moderate sized samples. For each scenario we simulated 1000 subjects 500 times.
In addition to the observed experience, the counterfactual, treatment-free experience
was generated for each subject in order to determine target values for β?, which, given
the complex data structure, were difficult to pre-specify. Independent adjustment co-
variates Zi1 and Zi2 were generated to follow a Bernoulli(0.5) distribution. Correla-
tion between recurrent events for each subject was induced through a frailty variate,
Qi, distributed Gamma with mean 1 and variance 0.5. The frailty was capped at
2, the 90th percentile. Pre-treatment recurrent event experience was then generated
though a frailty model with rate parameter Qidµ0 exp{α1Zi1+α2Zi2}. An additional
unobserved event process related to treatment was also generated using a similar
model to ensure dependent censoring. Treatment times, T Si , were then generated to
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follow the hazard λT0 exp{δ1Zi1 + δ2Zi2 + δ3 log(Ni1(t−) + 1) + δ4 log(Ni2(t−) + 1)},
where Ni1(t) is the outcome of interest and Ni2(t) is the unobserved event process
also related to treatment. The recurrent event times post-treatment were generated
from rate parameter Qidµ
T
0 exp{φ1Zi1 + φ2Zi2 + φ3 log(Ni(Ti) + 1)}.
Once the data were generated, prognostic scores representing pre-treatment event
trajectories were obtained from the model dµ0i (t) = exp{α01Zi1+α02Zi2+α03N0i (t−)}dµ00(t).
Subjects were matched if | log ψ̂ij| ≤ 0.025.
Parameters used in the simulation studies are as follows. For the pre-treatment
event rates, we set dµ0 = 3, α1 = 0.3, and α2 = −0.1 for the observed process and
dµ0 = 6, α1 = 0.3, and α2 = −0.1 for the unobserved process. For the treatment
hazard, λT0 = 0.01, δ1 = −0.2, δ2 = 0.1, δ3 = 0.2, and δ4 = 0.5. Finally, for the
post-treatment event rate, dµT0 was given values of 1, 1.5, 2, 3, 4, and 5, φ1 = 0.3,
φ2 = −0.1, and φ3 = 0.2. This resulted in values of β? of -0.265, -0.002, 0.206, 0.514,
0.751, and 0.945. In the simulated data 9.13% of the sample received treatment, and
the mean number of events was 12.4 (sd = 9.8).
Results from the simulations are shown in Table 2.1. Absolute bias ranged from
0.005 to 0.016, and coverage probabilities ranged from 0.91 to 0.94, close to the target
level of 0.95. Histograms of the difference between the estimated and target values
of β? are shown in Figure 2.1. They show a relatively normal distribution centered
at zero, supporting the claim that β? is unbiased and asymptotically normal. The
robust variance estimator performed well in this setting, with asymptotic standard
error estimates similar to their empirical counterparts. This will be discussed further
in Section 2.5.
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Table 2.1: Simulation results for proposed method estimating rare time-dependent treatment effects
on the recurrent event rate
Scenario dµ10 β? Estimate Bias ESE ASE CP
1 1.0 −0.265 −0.271 −0.005 0.084 0.078 0.91
2 1.5 −0.002 −0.013 −0.010 0.078 0.074 0.94
3 2.0 0.206 0.189 −0.016 0.077 0.071 0.93
4 3.0 0.514 0.506 −0.008 0.072 0.068 0.93
5 4.0 0.751 0.742 −0.009 0.071 0.066 0.92
6 5.0 0.945 0.930 −0.015 0.072 0.065 0.92
ESE=empirical standard error; ASE=asymptotic standard error;
CP=coverage probability
Figure 2.1: Histogram of parameter estimates from proposed method estimating rare time-
dependent treatment effects on the recurrent event rate with normal density
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Table 2.2: Simulation results for proposed method with increasing percent treated demonstrating
bias due to dependent censoring
Scenario % Treated β? Estimate Bias ESE ASE CP
1 9.44 −0.305 −0.262 0.043 0.118 0.108 0.89
2 24.82 −0.314 −0.276 0.038 0.073 0.071 0.91
3 36.69 −0.330 −0.280 0.050 0.066 0.062 0.87
4 56.66 −0.361 −0.292 0.069 0.062 0.057 0.74
5 68.71 −0.387 −0.300 0.086 0.066 0.057 0.62
6 85.62 −0.443 −0.305 0.138 0.075 0.062 0.42
ESE=empirical standard error; ASE=asymptotic standard error;
CP=coverage probability
2.3.2 Investigation of dependent censoring
Recall that subjects are censored from strata in which they serve as controls if they
subsequently receive treatment. Since treatment depends on, among other things,
the event history, this will result in dependent censoring in cases where treatment is
not rare. We used simulation to explore the point at which more common treatments
result in substantial bias. To do this we simulated 500 patients using a similar set
up to that of the previous section except that dµT0 was set at 1 and λ
T
0 took on
values of 0.01, 0.05, 0.15, and 0.3. This resulted in 9.44%, 24.82% 36.69%, 56.66%,
68.71%, and 85.62% of subjects receiving treatment, respectively. Results of these
simulations are shown in Table 2.2.
As shown in Figure 2.2, increasing the proportion of subjects treated increases bias
and decreases coverage probability. At approximately one-third of subjects treated
bias is at 0.05, and this almost triples to 0.14 when 86% of subjects are treated, with
increased bias resulting in lower coverage. Bias and coverage are similar from 10-25%
treated, likely due in this case to the smaller absolute number of treated subjects.
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Figure 2.2: Bias and coverage probability with increasing percentage treated
Given this trajectory we recommend that if the proportion of treated patients is less
than 20% methods such as IPCW aimed at correcting dependent censoring are not
necessary, however, once the proportion of treated subjects exceeds 20% weighting
is necessary to correct bias.
2.4 Application to Liver Transplantation
Development of End Stage Renal Disease (ESRD) post-liver transplant leads to
increased patient morbidity and mortality, and places increased burden on heath care
resources. We will use the proposed method to evaluate effect of ESRD development
post-liver transplant on the number of days hospitalized in the Adult-to-Adult Living
Donor Liver Transplantation Cohort Study (A2ALL). In this setting the “treatment”
of interest is development of ESRD, defined as initiation of dialysis or kidney trans-
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plant post-liver transplant. As mentioned previously, the proposed method is gen-
eralizable to time-dependent state changes such as development of post-LT ESRD.
In this setting we utilize time-dependent markers of kidney function such as crea-
tinine to estimate the hopitalization trajectory from the time of transplant to the
development of ESRD, and use these to match with patients on similar trajectories
that do not develop ESRD. Comparing the rate of days hospitalized for a patient
that develops post-LT ESRD compared to the rate that would have been observed
had the patient not developed ESRD is a critical component to the estimation of the
costs of post-LT care.
A2ALL is a multi-center NIH-funded consortium composed of 12 North American
transplant centers. Potential living donor liver transplant (LDLT) recipients trans-
planted between January 1, 1998 and January 31, 2014 were enrolled. Retrospective
and prospective data collection included post-transplant vital status and laboratory
information as well as hospitalization admission and discharge information. Data
were supplemented from the Scientific Registry of Transplant Recipients (SRTR).
The SRTR data system includes data on all donors, wait-listed candidates, and
transplant recipients in the United States; these data are submitted by the members
of OPTN and have been described elsewhere. The Health Resources and Services
Administration (US Department of Health and Human Services) provides oversight
for the activities of the OPTN and SRTR contractors.
There were 55 ESRD events out of 1447 transplanted patients in A2ALL. Median
post-transplant follow-up time was 5 years, and the average number of days hospi-
talized per patient year was 14.9 for non-ESRD patients and 37.2 for ESRD patients
(median days 2.3 and 5.1, respectively). Hospitalization admissions that occurred
after discharge from the transplant hospitalization but before onset of ESRD were
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Figure 2.3: Distribution of prognostic score distance from index ESRD patient with and without
matching
used to build the prognostic model, which was adjusted for the event history as well
as other transplant and post-transplant time-dependent predictors. Results from the
prognostic model are shown in Table 2.3. Each additional day of hospitalization
history was associated with a 2% increase in the rate of future hospitalization days
(p <0.001).
Using prognostic scores derived from the model in Table 2.3, the distribution of
prognostic score distance from index patient with and without matching is shown
in Figure 2.3. Prior to matching on prognostic score the range of distance between
the index subject and matched controls spans from -7.2 to 5.4, with 98% of matched
controls within the interval [−1.5, 3.5] from the index subject. When the 55 patients
that developed ESRD post-transplant were matched to patients that had not yet de-
veloped ESRD based on prognostic score, with all control subjects within ±0.02, the
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Table 2.3: A2ALL analysis: Prognostic model of pre-ESRD rate of days hospitalized
Parameter Rate Ratio 95% Confidence Interval p-value
Recipient age at Transplant (ref=65+)
18−40 1.00 (0.95, 1.06) 0.873
40−50 0.77 (0.73, 0.81) <.001
50−55 0.79 (0.75, 0.83) <.001
55−60 0.78 (0.74, 0.82) <.001
60−65 0.87 (0.82, 0.92) <.001
Recipient diagnosis: HCV 1.07 (1.04, 1.10) <.001
African−American (ref=all others) 0.75 (0.71, 0.79) <.001
Diabetes 0.89 (0.86, 0.92) <.001
Ln(creatinine) (time−dependent) 1.31 (1.27, 1.35) <.001
Ln(bilirubin) (time−dependent) 1.09 (1.07, 1.10) <.001
Ln(albumin) (time−dependent) 0.36 (0.34, 0.38) <.001
Donor age (ref=70+)
<18 0.64 (0.55, 0.74) <.001
18−40 0.76 (0.67, 0.87) <.001
40−50 0.78 (0.69, 0.89) <.001
50−60 1.02 (0.90, 1.16) 0.722
60−70 0.72 (0.63, 0.83) <.001
DCD (ref=non−DCD) 1.33 (1.21, 1.47) <.001
Regional (ref=Local) 1.32 (1.25, 1.40) <.001
National (ref=Local) 1.41 (1.32, 1.51) <.001
Split Liver 1.18 (1.08, 1.29) <.001
Living Donor (ref=Deceased Donor) 0.96 (0.88, 1.05) 0.397
Hospitalization History (per day) 1.02 (1.02, 1.02) <.001
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distribution of score distance is much tighter around zero. The matching resulted in
a median of 14 matches, with 6 (11%) patients that developed ESRD being excluded
due to lack of matches.
The proposed method was then used to fit a stratified model to determine the
effect of ESRD on the rate of days hospitalized (Model I) using model (2.10). The
following traditional time-dependent proportional rates models were also fitted where
ESRD status was treated as a time-dependent predictor adjusted for the same pre-
dictors in the prognostic model (Table 2.3):
µi(t) = µ
0
i (t) exp{θIII(Ti ≤ t) + βTZi(t)}(2.19)
and
µi(t) = µ
0
i (t) exp{θIIII(Ti ≤ t) + βTZi}.(2.20)
In the first model, model (2.19), additional time-dependent predictors thought
to be associated with the progression to ESRD were included, such as lab values
and hospitalization history, while in second model, (2.20), only baseline, i.e. at
transplant, values of these predictors were used. The results from all three models
are shown in Table 2.4. In Model I, which uses the proposed method, patients that
develop ESRD have a rate of days hospitalized that is 2.9 times higher than patients
that have not yet developed ESRD. By contrast, results from Model II give a rate that
is only 1.4 times higher for patients that have developed ESRD, but this comparison
is to patients without ESRD that have the same lab values and hospitalization history
at time t. By contrast, adjusting only for baseline values of factors associated with
the development of ESRD (Model III) estimates that patients that develop ESRD
have a days hospitalized rate 3.2 times higher than patients that do not have ESRD
at time t and were similar at transplant. This comparison demonstrates how use of
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Table 2.4: A2ALL analysis of the effect of post-LT ESRD development on the rate of days hospi-
talized: Comparison of proposed method with traditional approaches
Model Equation Parameter RR 95% CI p-value
I: Proposed Method (10) β? 2.90 (1.69, 4.97) <0.001
II: Time-dependent Adjustment Covariates (16) θII 1.44 (1.35, 1.53) <0.001
III: Baseline Adjustment Covariates (17) θIII 3.17 (3.01, 3.35) <0.001
RR=Rate Ratio; CI = Confidence Interval
the proposed method balances the opposing biases of over- and under-adjustment.
As a sensitivity analysis we also tested interactions with time since development of
ESRD and time of development of ESRD, but no significant variations in the effect
of ESRD development were found (both rate ratios ≈ 1, p = 0.23 and p = 0.68,
respectively).
2.5 Discussion
In this chapter we lay out a two-stage method for estimating the effect of time-
dependent treatments on recurrent events using an extension of the method of se-
quential stratification. The method proposed is partly conditional in the sense that
information up until treatment time, s, is used in the prognostic model, but the final
model for µ?ij(t; s) does not condition on covariates after s. A purely conditional
model (e.g. Anderson and Gill, 1982), which would include covariate information
on [s, s+ t), would tend to dampen the effect of treatment because it would require
comparison subjects to have the same history at the time of treatment. A marginal
analysis such as that of Lin et al (2000), on the other hand, would exaggerate the
effect of treatment because since treatment depends on the history, subjects that
receive treatment at time s may differ from those that do not. Our method ensures
subjects are similar up to s through conditioning, and is marginal thereafter, so that
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the post-treatment comparison averages over the treatment-free experience of the
matched controls.
The opposing biases of baseline and time-dependent adjustment in traditional
time-dependent models is demonstrated in the application to development of post-
liver transplant ESRD in the A2ALL study. While all three methods produced
significant results, the fully time-dependent model, which included a time-dependent
indicator for development of ESRD as well as time-dependent lab values and pre-
vious number of days hospitalized, all factors associated with progression of renal
failure, underestimated the effect of ESRD on the rate of days hospitalized by almost
half, while the similar model with only baseline factors associated with the develop-
ment of ESRD (i.e. at transplant values), overestimated the effect. In addition, the
comparison groups for these models are not constructed in a way that gives the de-
sired interpretation, i.e. a comparison of the event rate in the time period following
treatment in the presence and absence of treatment.
Note that the outcome chosen in the application was days hospitalized instead
of hospital admissions. Analyses of hospital admissions often ignore the fact that
patients are not at risk for hospitalization during the period in which they are in the
hospital. This can be accounted for by removing the duration of hospitalization from
the risk set, however, this step is often ignored. Modeling days hospitalized instead
of hospital admissions automatically removes this potential for error, however, in
some situations, hospital admissions may be a more relevant outcome.
As mentioned previously, it follows from the dependence of treatment initiation
on the event history that censoring of matched controls due to treatment would
constitute dependent censoring. We have shown that when the treatment is rare,
bias is not substantial, and therefore IPCW to correct for dependent censoring is not
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necessary. However, for more common treatments, bias will be induced and therefore
some sort of weighting must be done to preserve the unbiased properties of β?.
It should also be noted that while the sandwich estimator performed well in the
setting of rare treatment, issues related to the limiting value of Z?(u; s) may affect
variance estimates. In particular, the condition that Z?(u; s) converges to a constant
z?(u; s) is difficult to justify in this setting because the component of Z
?
i (s) corre-
sponding to treatment will always equal 1 within stratum j due to the continuous
time scale, and as n→∞ this will not change. The performance of the asymptotic
variance estimator in this setting does not imply equivalent performance in more
complex settings, such as those described in subsequent chapters. One potential
solution to this issue is to use a discrete time scale, as is often done in practice. If
patients receive treatment within a given unit of discrete time (e.g. day, week) and
match on prognostic score, the group of treated patients could then be matched to
appropriate controls. In this setting, as n→∞, a limiting value of Z?(u; s), z?(u; s),
is a more defensible assumption. In finite samples, however, where increasing the
number of treated patients per stratum is not feasible, and the data structure is
more complex than that described in this chapter, this problem may persist. Poten-
tial solutions to this issue, including additional variance estimation procedures, are
described in Chapters III and IV.
The proposed method makes use of the prognostic score in order to match as
yet untreated patients into strata. Another viable alternative would be propensity
matching (Rosenbaum and Rubin, 1983), i.e., matching on the probability of receiv-
ing treatment. A time-dependent propensity score has been proposed by Lu (2005),
and could be used in this setting. Our goal, however, was to create a comparison
group that mirrored the treatment-free experience of a subject treated at time s. It
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was therefore necessary to ensure that the event trajectories up until s were the same
between treated and control subjects, a property that the propensity score does not
preserve. Some combination of prognostic and propensity scores could also be used.
One limitation of the proposed method is that it does not account for terminating
events that halt all further occurrences of the recurrent event. The terminal event
is often correlated with the recurrent event, and when treated as a censoring mech-
anism, can result in dependent censoring. Numerous methods for the simultaneous
modeling of recurrent and terminal events are currently available. Marginal models
of recurrent events while subjects are alive have been described by Cook and Lawless
(1997) and Ghosh and Lin (2000). Joint modeling methods where the recurrent and
terminal event processes are linked through a subject-level random effect have been
proposed by Liu et al. (2004), Ye et al. (2007), Kalbfleisch et al. (2013), and others.
Development of these methods in the setting described above is explored in Chapter
IV.
CHAPTER III
Time-dependent prognostic score matching for recurrent
event analysis with a common multi-state treatment
3.1 Introduction
Events that can occur repeatedly for the same subject are often of interest in
clinical settings. Examples include repeated hospitalizations, post-surgery compli-
cations, viral infections, or myocardial infarctions. Many methods for modeling
recurrent events have been described in the literature, including conditional models
(e.g., Andersen and Gill, 1982; Pepe and Cai, 1993) and marginal approaches (Law-
less and Nadeau, 1995; Lin et al., 2000; Pena, Strawderman and Hollander, 2001). A
comprehensive survey of methodology for recurrent events is provided by Cook and
Lawless (2007).
It may be of interest to study recurrent events as a basis for evaluating a treatment,
and a limited number of methods are available for this purpose (e.g., Cook et al.,
2009; Schaubel and Zhang, 2010). For chronic conditions, it is often the case that
treatment begins some time after the start of follow-up, such that treatment is time-
dependent. Although methods exist for analyzing recurrent events in the presence
of time-varying covariates (Chen et al., 2013), such methods were not designed for
evaluating treatments. Most recurrent event methods assume that time-dependent
elements are external (Kalbfleisch and Prentice, 2002), which essentially rules out
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their application to evaluate time-dependent treatments that are not randomized.
In the setting we consider in this report, treatment is time-dependent, in that
subjects typically begin follow-up untreated, with some going on to receive treat-
ment. Two forms of treatment are available, a new ‘experimental’ treatment and
the standard treatment. The conventional course for a subject is to start follow-up
untreated, then possibly receive the standard treatment. Our objective is to com-
pare the recurrent event rate for subjects receiving the experimental treatment to
that which they would have experienced under conventional therapy (which would
be a combination of ‘untreated’ and ‘standard treatment’). In Figure 3.1, we de-
pict the recurrent event experience of the same subject i under two scenarios. For
the top time line, subject i receives the experimental treatment at follow-up time
s; after time s, the event course changes in relation to what it would have been on
conventional therapy. The bottom time line pertains to the same subject, but under
a scenario where experimental treatment does not exist. The comparison of interest
is the ratio of the recurrent event rates t time units following time s. Note that
the comparison of interest begins at the time of experimental treatment initiation, s,
since the experimental treatment would clearly have no effect on subject i during the
[0, s) time interval. Ideally, we would like to compare each experimentally treated
patient with their ‘ghost’, who remains on the conventional course; naturally, we
never observe the latter if we observe the former.
Additional features of the data structure we consider are as follows. There are lon-
gitudinal measures available on each subject; i.e., time-dependent covariates. More-
over, the event history itself (e.g., up to the time of treatment) naturally provides
information on the anticipated event rate (e.g., post-treatment). Treatment is not
randomized, and generally depends on the time-varying covariates and the observed
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Figure 3.1: Recurrent event process for subject i under in the presence and absence of experimental
treatment.
recurrent event experience. Finally, the experimental treatment effect may not be
homogeneous and could be modified by the time-dependent entities.
The above-described data structure arises in the study of hospitalization rates
after living donor liver transplantion (LDLT). The standard treatment for end-stage
liver disease (ESLD) is deceased donor liver transplantation (DDLT). However, LDLT
is a relatively new treatment option for ESLD that involves using a partial graft from
a living donor in place of the traditional whole graft from a deceased donor. Our
goal is to compare hospitalization rates for a patient who receives an LDLT relative
to what that patient’s hospitalization rate would have been had they remained on
the waiting list and potentially received a DDLT.
Note that a traditional analysis (e.g., proportional rates model) featuring a time-
dependent experimental treatment indicator 0/1 would generally produce a biased
estimate of the contrast of interest (described in the preceding paragraph). This is
largely due to the comparison groups having not been constructed appropriately (i.e.,
in a manner which respects the timing of the treatment assignments across subjects).
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We illustrate this phenomenon in Section 3.4 through the data set which motivated
our work.
Since it is not possible to observe the treatment-free event process for subjects
that undergo treatment, a potential alternative is to compare those who receive
a certain time-dependent treatment at time s to other similar subjects who were
eligible to receive the treatment at time s but do not. The averaged event rates
after s of matched subjects are then compared to the post-treatment event rate of
the index subject. Methodology for this type of analysis currently exists for the
univariate survival setting (Schaubel et al., 2009). In the current report, we extend
this method to the recurrent event setting.
There are several key differences in the methods we propose in this report and
those of Schaubel et al. (2009). First, the outcome is a recurrent event and, hence,
more complex than a survival time. Second, we use a two-stage modeling approach.
The first stage features a conditional rate model intended, not for interpretation, but
to track each patient’s recurrent event history and projected prognosis. The linear
predictor from the Stage 1 model is used at Stage 2 to caliper-match each patient
receiving the experimental treatment to yet-untreated patients as opposed to the
hard matching and covariate adjustment used by Schaubel et al. (2009). The final
model for the recurrent event rate then consists only of the treatment effect and
a distance measure which accounts for any small differences in the pre-treatment
event trajectories between the experimental patient and the matched controls. The
matching we propose in this report aims to create counterfactual ‘ghosts’ to recover
the conventional therapy experience of the experimentally treated patients.
The remainder of this report is organized as follows. In Section 3.2, we introduce
the notation and describe the proposed methods, including parameter estimation
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and inference. A simulation study is presented in Section 3.3. In Section 3.4, the
proposed methods are applied to data from the Adult-to-Adult Living Donor Liver
Transplantation Cohort Study (A2ALL) to estimate the impact of LDLT on hospital
admission rates relative to conventional therapy (remaining on the wait list and
potentially receiving a DDLT). Some concluding remarks are offered in Section 3.5,
including areas of future work and work currently in progress.
3.2 Methods
3.2.1 Notation and Data Set-up
In the development that follows, i represents subject (i = 1, . . . , n). The time-
dependent covariate for subject i is denoted Z∗i (t). Subjects are generally untreated
at time 0, with treatment time given by Ti = T
E
i ∧ T Si , where TEi represents the
time of ‘experimental’ treatment initiation, T Si denotes time of ‘standard’ treatment
initiation and a ∧ b = min (a, b). Note that at most one of TEi and T Si occurs.
Treatment (be it experimental or standard) is assumed to be non-reversible, in the
sense that patients are considered ‘treated’ from the time of treatment initiation
forward. The true number of events for subject i in [0, t] is defined as N∗i (t) =∫ t
0
dN∗i (u). Event and treatment times are subject to independent right censoring by
Ci. The number of observed events is given by Ni(t) =
∫ t
0
I(Ci > u) dN
∗
i (u). Note
that right censoring is administrative in this setting.
To fix ideas, we make the distinction between ‘treatment’ and ‘therapy’. In par-
ticular:
• There are two forms of treatment: standard and experimental
• Conventional therapy involves the treatment course that all patients would need
to follow if the experimental version of the treatment did not exist. Under
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conventional therapy, patients begin follow-up untreated, with some going on to
receive the standard treatment.
Our definition of therapy as being a sequence of treatments is not standard, but
allows for convenient labeling. While untreated, a patient is actually following con-
ventional therapy, with experimental treatment being initiated at time TEi . An un-
treated patient who later receives standard treatment is also following conventional
therapy.
We define several event counting processes. The number of pre-treatment events
in (0, t] is given by
N0i (t) =
∫ t
0
I(Ti > u) dN
∗
i (u).
Consider patient i at follow-up time s under two scenarios. In the first scenario,
patient i receives the experimental treatment at time s; i.e., TEi = s. The pertinent
post-experimental treatment event counter is defined as
N?i (t; s) = I(T
E
i = s)
∫ s+t
s
dN∗i (u).(3.1)
Note that it will be our convention that N(t; s) refers to the interval of length t, but
starting at time s; a single time index, as in the previously-defined N0i (t), pertains to
the (0, t] time interval. Correspondingly, we define an event counter representing the
events that would have been experienced in the absence of experimental treatment,
also beginning at time s,
NCTi (t; s) = I(Ti ≥ s)
∫ s+t
s
I(TEi > u)dN
∗
i (u),(3.2)
where the superscript CT denotes ‘conventional therapy’. Parallelling N?i (t; s), the
counter NCTi (t; s) tracks the patient on (s, s + t]. To emphasize the correspondence
between (3.1) and (3.2), consider a subject eligible to receive the experimental treat-
ment at time s, such that I(Ti ≥ s); note that I(Ti ≥ s) = I(TEi = s) ∪ (TEi >
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s, T Si > s). Under the setting where T
E
i = s, the counting process (3.1) takes effect;
had the experimental therapy not been an option, process (3.2) takes effect. An
important point is that the patient is untreated on (0, s) under either scenario to
which (3.1) and (3.2) pertain.
Finally, we define a 0/1 process for being observed to receive the experimental
treatment,
NEi (t) =
∫ t
0
I(Ci > u)dI(T
E
i ≤ u).(3.3)
As shown in Section 2.2, NEi (t) is used to fit a model needed for inverse weighting.
3.2.2 Proposed Models and Estimation Methods
As described above, the goal of this method is to compare the post-experimental
treatment recurrent event mean to the corresponding event mean under conventional
therapy (CT). For a subject with TEi = s, the comparison would be on (s, s+ t] for
t > 0, such that the pertinent counting processes are given in (3.1) and (3.2). We
denote the mean of (3.1) by
µ?i (t; s) = E
[∫ t
0
N?i (du; s)|TEi = s,H i(s)
]
,(3.4)
where H i(s) = {Z∗i (u), Ni(u), I(Ti > u), I(Ci > u); 0 ≤ u < s} represents the
observed pre-treatment history for subject i on [0, s). As we describe shortly, we
avoid explicitly modeling (3.4). Note that (3.4) represents a partly conditional model
(Pepe and Couper, 1997; Zheng and Heagerty, 2005; Gong and Schaubel, 2013) since
it conditions on the history only up to time s, not s+ t. We make this choice for the
sake of interpretation, but it is not without consequences with respect to parameter
estimation, as detailed shortly. This idea of conditioning on only part of the history
is connected to landmark analysis (van Houwelingen, 2007; van Houwelingen and
Putter, 2008; 2012).
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Having defined the post-experimental recurrent event mean in (3.4), the corre-
sponding quantity (in the absence of experimental treatment) is given by
µCTi (t; s) = E
[∫ t
0
NCTi (du; s)|H i(s), Ti > s, TEi > u
]
,(3.5)
which, like (3.4), we avoid modeling directly. The model of chief interest is then
given by
µ?i (t; s) = µ
CT
i (t; s) exp{β?},(3.6)
which can equivalently be expressed in terms of a rate function by
µ?i (dt; s) = µ
CT
i (dt; s) exp{β?}.(3.7)
In this model µCTi (t; s), the experimental treatment-free mean number of events is
scaled up or down by exp{β?} if subject i received the experimental treatment at
time s. The mean number of post-experimental treatment events is then compared
to the mean number of experimental treatment-free events after time s.
More general versions of model (3.7) are possible, including
µ?i (dt; s) = µ
CT
i (dt; s) exp{β?(t; s)},(3.8)
where β?(t; s) is a parametric function of both time of experimental treatment initi-
ation (given by s) and time since TEi = s, given by t. Model (3.8) is more flexible, in
the sense that the effect of receiving the experimental treatment, on the event rate,
can depend on the time until and time since treatment was received.
In reality, once a subject receives the experimental treatment, we can no longer
observe the subject’s experience receiving conventional therapy. Therefore, a patient
experimentally treated at time s will be compared to similar patients who did not
initiate experimental treatment at follow-up time s but were eligible to do so. Similar
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to Schaubel et al. (2009), we use the concept that each experimental treatment
time initiates an “experiment”, in which the recipient of the experimental treatment
is compared to ‘similar’ treatment-eligible candidates. Note that ‘similar’, in this
context, refers to current status (i.e., at time s) and history on [0, s). Eligibility for
the comparison is defined as
ei(s) = I(T
E
i = s) + I(Ti > s),
i.e., at time s, patient i either received the experimental treatment or remained
untreated.
Our method of estimating β? from (3.7) involves a stratified analysis, as will be
formalized shortly. Each experimental treatment patient generates a stratum, which
will include the index patient as well as similar treatment-eligible patients. The
most relevant definition of similar, here, is with respect to treatment-eligibility at s,
denoted by ei(s), and accumulated covariate and recurrent event history on (0, s],
represented byH i(s). In order to quantify each subject’s history, we use a prognostic
score (Hansen, 2008) based on the pre-treatment event rate, modeled using a time-
dependent proportional rates model,
dµ0i (t) = E [dN
∗
i (t)|H i(t), Ti > t] = exp{αT0Zi(t)}dµ0(t),(3.9)
where the covariate Zi(t) is chosen to capture the pertinent components of the his-
tory, E[dN∗i (t)|H i(t), Ti > t] = E[dN∗i (t)|Zi(t), Ti > t]. Model (3.9) resembles the
Lin et al. (2000) model, but is more accurately interpreted as an Andersen-Gill
(1982) model, due to the explicit dependence on the prior event history, a property
avoided by Lin et al. (2000). The regression parameter α0 from (3.9) can be com-
puted by solving the unweighted Cox (1972) score equation. Due to the dependence
on internal covariates (Kalbfleisch and Prentice, 2002), elements of α0 are difficult
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to interpret. This is not a problem, in our case, since we do not care to interpret,
let alone carry out inference on α0. Note that we focus on untreated experience
since, at any time s, the patient generating the stratum (by initiating the experi-
mental treatment) and the potential matches are all necessarily untreated with either
experimental or standard treatment on [0, s).
The purpose of the prognostic score is to match patients that have similar pre-
treatment event rates, the rationale being that previous event rate is the most im-
portant predictor of the current event rate. Unlike a propensity score, which uses the
treatment event rate to match subjects with similar probabilities of being treated,
the prognostic score aims to compare the effect of treatment on the event rate among
subjects that were on the same trajectory with respect to their pre-treatment event
rate. The use of prognostic scores in conjunction with, or as a alternative to, propen-
sity scores has been considered in several reports (e.g., Rubin and Thomas, 2000;
Stuart, Lee and Leacy, 2013; Leacy and Stuart, 2014; Li, Schaubel, and He, 2014)
and will be addressed further in Section 5. Once the prognostic scores have been
estimated, caliper matching is used to assign untreated control subjects to a subject
receiving the experimental treatment at time s. Caliper matching requires that the
prognostic scores of matched subjects be within a certain radius of the prognostic
score of the index subject. Appropriate selection of the caliper involves balancing
the need for homogeneity within-stratum with the need to have an adequate number
of matches for each index subject. We propose that prior to data analysis the caliper
size be chosen such that the median number of matches is between 10 and 20. It is
important to verify that some level of balance in the event rate at time s is achieved
with the chosen caliper. Methods for checking balance in propensity matching have
been discussed by Hansen (2008) and Harder, Stuart, and Anthony (2010). This will
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be explored further in the application to living donor liver transplant described in
Section 4. The discrepancy between prognostic scores for experimental subject j and
control subject i can be quantified through the subject-pair specific rate ratio,
ψi,j(s) =
dµ0i (s)
dµ0j(s)
= exp{αT0 [Zi(s)−Zj(s)]}.
Subject i is considered to have a path on [0, s) sufficiently similar to subject j if
| logψij(s)| ≤ , where  > 0 is a pre-determined constant.
Combining the eligibility indicators and prognostic scores, patient i is included in
the stratum generated by patient j if mij(s) = 1, where
mij(s) = ei(s)I(Ti > s)ej(s)I(T
E
j = s)I(| log ψ̂ij(s)| ≤ ),
with ψ̂ij(s) = exp{α̂T0 [Zi(s)−Zj(s)]}. In order to account for the residual difference
between patients i and j, we propose to adjust for log ψ̂ij(s) in the final model.
Incorporating the eligibility indicator and the prognostic score distance, the final
fitted model for the event mean for stratum j is then
µ?ij(t; s) = mij(s)µ
CT
i (t; s) exp{β?I(TEi = s) + βψ log ψ̂ij(s)}.(3.10)
To clarify the representation in model (3.10), j is the stratum (generated by patient
j through TEj = s) and i is the patient within stratum. The model governs the
experimental patient through the indicator I(TEi = s), which equals 1 if i = j. The
vector of parameters to be estimated and the corresponding covariates are given by
β?ψ =
 β?
βψ
 Z?i (s) =
 I(TEi = s)
log ψ̂ij(s)
 ,(3.11)
such that model (3.10) can be re-written as µ?i (t; s) = mij(s)µ
CT
i (t; s) exp{βT?ψZ?i (s)}.
Subjects that are matched to the experimental subject enter the experiment with-
out receiving any treatment, but could subsequently receive either the experimental
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treatment or standard treatment. If a patient receives the standard treatment after
time s, follow-up in the experiment continues since the goal is to compare experi-
mental treatment to conventional therapy (i.e., beginning untreated and potentially
later receiving standard treatment). However, if a matched subject receives the ex-
perimental treatment after time s they are censored from all experiments in which
they serve as controls and begin their own experiment as the index subject. This
generally results in dependent censoring since, although dI(TEi ≤ s+ t) can be con-
sidered random given H i(s + t), the model for µ
?
ij(t; s) from (3.10) only conditions
on H i(s), the pre-treatment history up to time s. Since {H i(s + t); t > 0} can
affect dI(TEi ≤ s + t) and, by definition, affects Ni(t; s), the censoring of matched
controls via experimental treatment initiation constitutes dependent censoring.
We apply a variant of Inverse Probability of Censoring Weighting (IPCW; Robins
and Rotnitzky, 1992; Miloslavsky et al., 2004) to account for this dependent censoring
by modeling the censoring mechanism (experimental treatment) using the following
model,
λEi (t) = λ
E
0 (t) exp[β
T
EZi(t)],
fitted through standard partial likelihood (Cox, 1975).
3.2.3 Parameter Estimation
We now describe the estimation of the parameter of interest, β?, through the
estimation of β?ψ. To begin, we define the pertinent risk set indicator for stratum j,
Yij(t; s) = mij(s)I(Ci > s+ t){I(TEi = s) + I(TEi > s+ t)}.
For now, suppose that, subsequent to being matched to an index experimental treat-
ment patient j at time s, matched controls were randomly selected to receive exper-
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imental treatment given H i(s). In this restrictive case, the following process,
mij(s)
∫ s+t
s
Yij(u; s){Ni(du; s)− µi(du; s)}(3.12)
would have mean zero.
As mentioned above, we will use IPCW to account for censoring of matched
patients who receive the experimental treatment in each experiment. IPCW involves
weighting using the inverse probability of being censored or, in this case, receiving
the experimental treatment. Since the experiment begins at time s, the weight only
accounts for the probability of receiving the experimental treatment during [s, s+ t).
Correspondingly, we define the quantity
Gi(t; s) =
Gi(s+ t)
Gi(s)
= exp
{
−
∫ s+t
s
λEi (u) du
}
,
where
Gi(t) = exp
{
−
∫ t
0
λEi (u) du
}
.
The weight function can then be defined as
Wij(t; s) = Yij(t; s)Gi(t; s)
−I(TEi >s),
such that the index experimental treatment patient is appropriately self-weighting;
censoring after TEi can only occur independently via Ci.
Applying the weight function to (3.12) produces the zero-mean process,
mij(s)
∫ τ−s
0
Wij(u; s)Mij(du; s),(3.13)
where we define Mij(du; s) = Yij(u; s){Ni(du; s)−µij(du; s)}, with τ chosen to satisfy
P (Ci ≥ τ) > 0 and often set to max{C1, . . . , Cn}. Aggregating across subjects for
the experiment occurring at time s produces the set of zero mean processes,
∑n
i=1mij(s)
∫ t
0
Wij(u; s)Mij(du; s)(3.14)
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and
∑n
i=1mij(s)
∫ t
0
Z?i (s)Wij(u; s)Mij(du; s).(3.15)
We reorganize this system to solve implicitly for the baseline mean, µCT0 (u; s) in
(3.14), then substitute into (3.15). Then, aggregating across all experiments yields
the final estimating function for β?ψ,
U(β) =
n∑
j=1
n∑
i=1
∫ τ
0
mij(s)
∫ τ−s
0
{Z?i (s)−Z?(u; s)}Ŵij(u; s)Ni(du; s)dNEj (s),
(3.16)
where Ŵij(t; s) = Yij(t; s) exp{[Λ̂Ei (s+ t)− Λ̂Ei (s)]I(TEi > s)}, and with
Z?(u; s) =
∑n
`=1m`j(s)Ŵ`(u; s)Z
?
`(s) exp{βT?ψZ?`(s)}∑n
`=1m`j(s)Ŵ`(u; s) exp{βT?ψZ?`(s)}
.
Since U(β) from (3.16) behaves asymptotically like a zero-mean estimating function,
the solution to U(β) = 0, denoted by β̂?ψ , should yield a consistent estimator of
β?ψ.
3.2.4 Variance Estimation, Asymptotic Properties, and Inference
Due to the complex nature of the data structure in this setting we investigated the
use of both the robust sandwich estimator and the bootstrap estimator for variance
estimation and propose the use of the bootstrap estimator (Efron, 1979). In moder-
ate sized samples approximately 100 bootstrap samples should be used. If the normal
approximation is reasonable, 100 bootstrap samples should be adequate for hypoth-
esis testing and interval estimation. If the normal approximation is in question, then
upwards of 10,000 may be necessary to estimate the 2.5th and 97.5th percentiles of
the distribution for hypothesis testing. A straightforward pre-test method for de-
termining the number of necessary bootstrap samples is described by Davidson and
MacKinnon (2000).
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3.3 Simulation Study
Simulation studies were conducted to assess the performance of the method de-
scribed above. For each subject who received the experimental treatment, the sub-
sequent (counterfactual) experience (i.e., in the absence of experimental treatment
receipt) was also generated. This counterfactual experience was not used in the mod-
eling, but was used to determine target values of β?, which are difficult to pre-specify.
First, for each subject i, a frailty variate was generated from a Gamma (1, 0.5) dis-
tribution, bounded at 2, the 90th percentile. Next, two independent Bernoulli (0.5)
variates, Zi1 and Zi2 were created. Pre-treatment recurrent event experience was
then generated though a frailty model with rate parameter γidµ0 exp{α1Zi1+α2Zi2}.
The time of standard treatment receipt, T Si , was then generated to follow the haz-
ard λS0 exp{βS1Zi1 + βS2Zi2 + βS3 log(Ni(t−) + 1)}. The recurrent event times post-
standard treatment were generated from rate parameter γidµ
S
0 exp{δ1Zi1 + δ2Zi2}.
Thus, as mentioned in the first paragraph of this subsection, we initially gener-
ated the conventional therapy (pre-treatment plus post-standard treatment) recur-
rent event experience for all subjects. We then generated TEi from hazard function,
λE0 exp{βE1Zi1 + βE2Zi2 + βE3 log(Ni(t−) + 1)}. The experimental treatment was
only considered to actually be received if TEi < T
S
i and, in such cases, the post-
experimental recurrent event experience then followed rate model γidµ
E
0 exp{φ1Zi1 +
φ2Zi2}.
For each data set generated, we modeled the hazard for TEi using the model,
λEi (t) = λ
E
0 (t) exp{βE1Zi1 + βE2Zi2 + βE3 log(Ni(t−) + 1)}, in order to obtain the
estimated weights for IPCW. We then modeled the pre-treatment event rate using the
model dµ0i (t) = exp{α1Zi1 + α2Zi2 + α3N0i (t−)}dµ00(t), in order to obtain prognostic
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scores. Subjects were matched if | log ψ̂ij| ≤ 0.1, resulting in approximately 8 matches
per stratum.
Parameters used in the simulation studies are as follows. For the pre-treatment
event rate, we set dµ0 = 5, α1 = −0.3, and α2 = 0.7. For the post-standard
treatment event rate, dµS0 = 1, δ1 = −0.6, and δ2 = 0.2. For the experimental
treatment hazard, λE0 = 0.5, βE1 = −0.7, βE2 = −0.5, and βE3 = 0.3. For the
standard treatment hazard, λS0 = 0.5, βS1 = −0.8, βS2 = −0.7, and βS3 = 0.1.
Finally, for the post-experimental treatment rate, dµE0 was given values of 1, 1.5,
2.5, and 3, φ1 = −0.7, and φ2 = 0.7. This resulted in values of β? of -0.901, -0.457,
0.082, and 0.261. In the simulated data 63% of the sample received experimental
treatment, 36% received standard treatment, and 1% received no treatment. The
mean number of events was 9.46 (sd = 0.72) in the no treatment state, 18.92 (sd =
1.49) in the post-conventional treatment state, and ranged from 16.41 to 24.96 in the
post-experimental treatment state. These numbers describe the simulated data but
are not directly related to the different treatment effects tested, due to the timing of
experimental treatment. A total of n = 200 subjects were simulated 250 times, with
50 bootstrap samples used for variance estimation.
The results are shown in Table 3.1 for the estimate of the parameter for the
experimental treatment effect. Direct matching and prognostic matching gave similar
bias (range 0.022-0.029 and 0.015-0.030, respectively). However, prognostic score
matching resulted in empirical standard errors that were 9-10% lower. Adjusting for
logψij further reduces bias in the estimate of the experimental treatment effect (range
0.004-0.017 across the 4 scenarios). Figure 3.2 shows histograms of the parameter
estimates centered on their target value with normal density curves. All estimates
appear to follow a normal density centered at zero, supporting the theory that βˆ? is
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Table 3.1: Results of simulation study using proposed method to estimate the effect of a time-
dependent treatment on the recurrent event rate using IPCW
Scenario β? Matching Bias ESE ASE CP
1 -0.901 Prognostic 0.030 0.130 0.158 0.980
2 -0.457 0.029 0.127 0.151 0.972
3 0.082 0.024 0.121 0.142 0.972
4 0.261 0.015 0.119 0.140 0.976
1 -0.901 Prognostic 0.017 0.129 0.158 0.976
2 -0.457 w/adjustment 0.017 0.125 0.153 0.980
3 0.082 0.012 0.120 0.144 0.984
4 0.261 0.004 0.118 0.141 0.976
1 -0.901 # of Events 0.022 0.142 0.188 0.988
2 -0.457 with Covariate 0.027 0.140 0.181 0.976
3 0.082 Adjustment 0.029 0.135 0.172 0.976
4 0.261 0.024 0.133 0.170 0.980
ESE=empirical standard error; ASE=asymptotic standard error;
CP=coverage probability
asymptotically normal with mean β?.
3.4 Application to Living Donor Liver Transplant
The Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)
is a multi-center NIH-sponsored study investigating the post-transplant morbidity
and mortality of LDLT recipients and their donors. Potential living donor trans-
plant recipients who had a donor evaluated between January 1, 1998 and August 31,
2009 were recruited at each of the 9 A2ALL centers beginning in the third quarter of
2004 and followed through August 31, 2010. These potential recipients may have ul-
timately received an LDLT, a DDLT, or neither. Clinical data, including laboratory
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Figure 3.2: Histogram of parameter estimates from proposed method to estimate the effect of a
time-dependent treatment on the recurrent event rate using IPCW with normal density
information, hospitalizations, and complications were collected based on a common
protocol, and supplemented with data from the Scientific Registry of Transplant
Recipients (SRTR). The SRTR data system includes data on all donors, wait-listed
candidates, and transplant recipients in the United States; these data are submitted
by the members of OPTN and have been described elsewhere. The Health Resources
and Services Administration (US Department of Health and Human Services) pro-
vides oversight for the activities of the OPTN and SRTR contractors. Data col-
lection for pre- and post-transplant hospitalizations included date of admission and
discharge, reason for hospitalization, and discharge diagnosis. Subjects could enroll
either before or after transplant, and information prior to enrollment was collected
via chart review.
LDLT is a technically complicated surgery. Since we essentially wish to eval-
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uate whether LDLT results in a higher post-transplant hospitalization rate than
conventional therapy, our objective is consistent with a non-inferiority test. The
comparison of interest is between LDLT recipients and their counterparts who re-
main on the waiting list and potentially receive a DDLT. The time origin was date
of first donor evaluation. This analysis includes 1467 liver transplant candidates, of
which 714 went on to receive an LDLT, 455 received a DDLT, and 298 remained
untransplanted.
The pre-treatment model for the event rate was adjusted for age, race, recipient
diagnosis, Model for End Stage Liver Disease (MELD), event history (previous num-
ber of hospital admissions), and the following characteristics measured at the time
of donor evaluation: hospitalization status, ascites, mechanical ventilation, dialysis
status, and transplant center. Subjects with | logψij(s)| ≤ 0.025 who were untrans-
planted at the time of LDLT were matched. This resulted in a median of 20 matches
(range 1-71, IQR 11-34). Of the 714 LDLTs, 692 (97%) were matched to at least one
“control” subject. The mean log ψ̂ij(s) was 0.000033 (SD = 0.014), indicating that
the index patients and their matched counterparts were very similar at the time of
matching, with respect to prognosis.
Both traditional time-dependent models and models using the proposed method
were fitted. The time-dependent model was adjusted for age, ethnicity, diagno-
sis, MELD, transplant center, diabetes and ascites at the time of donor evaluation,
and event history defined as above. In the model using the proposed method 100
bootstrap samples were generated to estimate the variance of parameter estimates.
Table 3.2 shows the results of two models, one using only a main effect for LDLT
and another using an interaction between LDLT and MELD score, each fit for both
methods mentioned above (a total of four models). In the time-dependent version
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Table 3.2: A2ALL results: Effect of LDLT on hospital admission rate
Proposed Model Time-dependent Model
Model Rate Ratio 95% CI p-value Rate Ratio p-value
1 LDLT 0.986 0.857-1.134 0.8425 1.217 <0.0001
2 LDLT MELD 6-11 1.152 0.849-1.562 0.3628 1.606 <0.0001
LDLT MELD 12-15 0.962 0.752-1.230 0.7589 1.351 <0.0001
LDLT MELD 16-19 0.915 0.696-1.202 0.5226 1.009 0.8906
LDLT MELD 20-29 0.918 0.702-1.202 0.5344 1.040 0.5483
LDLT MELD 30-40 1.150 0.136-9.702 0.8978 1.143 0.3148
CI=confidence interval
of Model 1, LDLT recipients have a significantly higher rate of hospitalizations com-
pared to the combination of waiting list patients and DDLT recipients (rate ratio
[RR] = 1.22, p <0.0001), consistent with Merion et al, 2010. However, using the pro-
posed methods, there is no difference in hospitalization rates between subjects who
receive LDLT and those receiving conventional therapy (RR = 0.986, p = 0.8245).
We also fit models with interactions between LDLT and MELD (Model 2). In the
time-dependent model lower MELD subjects receiving LDLT had significantly higher
hospitalization rates, with a rate ratio of 1.606 for subjects with MELD 6-11 and
1.351 for subjects with MELD 12-15 (p <0.0001 in both cases). Subjects receiving
LDLT in higher MELD categories did not have significantly different hospitaliza-
tion rates relative to subjects waiting for DDLT. Similar to the main effect model,
the higher hospitalization rates in low MELD subjects receiving LDLT are not seen
when the proposed method is used. Rate ratios range from 0.915-1.152 with p-values
ranging from 0.3628-0.8978.
One potential reason for the differing results between the two methods is that in
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the proposed model patients are matched on pre-transplant event rate on the day of
the index transplant, so the method compares the LDLT patient to patients with a
similar pre-transplant event history. By contrast, in the traditional time-dependent
analysis, pre- and post-transplant event rates are averaged over in both the LDLT
and non-LDLT groups; patients in the comparison group may have differing event
rates at the time a given subject receives an LDLT. To explore this further we
investigated interactions with time and LDLT using the proposed method to explore
potential differences in the rate ratios over time. Figure 3.3 shows that there is
a sharp increase in the hospitalization rate immediately after LDLT. However, the
RR declines quickly, to the point where it is significantly below 1 for a period, then
continues to rise for the remainder of follow-up. The estimated RR actually rises
above 1 (although non-significantly) towards the end of the follow-up period. The
pronounced and steady rise in the RR (after the drop to significantly below 1) is due
to the nature of the comparison groups. Specifically, as time progresses, a greater
percentage of subjects in the conventional therapy groups are DDLT (as opposed
to pre-transplant) patients. If the comparison were between experimental treatment
and pre-transplant, then it is highly likely that the RR may have stabilized.
3.5 Discussion
Despite the wide array of methods available for modeling recurrent event data,
there are relatively few such methods devoted specifically to estimating the effect of
treatment. A limited number of methods have been developed to accommodate time-
dependent covariates and informative censoring (e.g., Huang, Qin and Wang, 2010;
Zhao et al, 2012). However, such methods apply under different data structures and
assumptions. Our goal in this report was to develop methods to estimate treatment
50
Figure 3.3: Time-dependent rate ratio (RR) for LDLT and 95% confidence intervals
effects in a fairly complex setting: treatment is time-dependent, different forms of
treatment are available, and the event rate in the absence of the treatment of interest
is dependently censored.
One key aspect to this type of analysis is appropriate matching of control sub-
jects to experimental subjects. In the method proposed prognostic scores were used
to match index patients to control patients within a certain radius. It should be
noted that this is slightly different than the usual prognostic score setting because
all patients are observed in the untreated state for some period of time, not only
the control patients, and thus all patients contribute to the event rate model used
to generate the prognostic scores. An alternative would be to use k-nearest neigh-
bor matching. However, this method appears to be less appropriate for two reasons.
First, while some experimental patients may have many appropriate matches, requir-
ing a pre-specified number of matches per experimental patient could result in large
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heterogeneity in some strata. Second, Abadie and Imbens (2008) have demonstrated
that the bootstrap estimator is invalid in the setting of nearest neighbor matching.
It could also be argued that propensity matching would be an appropriate matching
method for this data structure. In that scenario the goal would be to simulate a
randomized trial by matching patients with similar probabilities of receiving exper-
imental treatment. A time-dependent propensity score similar to that proposed by
Lu (2005), may be appropriate.
A limitation to the method as described is that it does not take into account
terminal events such as death. Many methods for recurrent/terminal event data
have been proposed (e.g., Ghosh and Lin, 2002; Liu, Wolfe and Huang, 2004; Huang
and Wang, 2004; Ye, Kalbfleisch and Schaubel, 2007; Kim et al., 2012, Kalbfleisch
et al., 2013) and could be applied to the method described above. Extension of
the proposed methods to incorporate terminal events is described in the following
chapter.
CHAPTER IV
Estimating time-dependent treatment effects for correlated
recurrent and terminal events
4.1 Introduction
In most clinical settings a recurrent event process can be stopped by a terminal
event such as death. Events such as hospitalizations, infections, or myocardial infarc-
tions cease to occur once a patient dies. If the recurrent event process is independent
of the terminal event then parameter estimates measuring the effects of covariates
of interest on the recurrent event rate remain unbiased. The assumption of indepen-
dence is a strong one and is not often justifiable in practice. It is more often the case
that an increase in the recurrent event rate increases the probability of the terminal
event occurring, which means that methods which treat the terminating event as
independent censoring generally lead to biased estimation.
Under the framework we consider in this chapter, recurrent events are stopped,
not censored by, the terminal event. This is in contrast to some proposed methods
which view the recurrent event process as a latent process that continues, unobserved,
after the terminal event occurs. Methods using this framework have been proposed by
Ghosh and Lin (2003) and Miloslavsky (2004), and adapt methodology for dependent
censoring to this setting. If the terminal event is something other than death, such as
study termination for medical reasons, then this framework and associated estimation
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methods are applicable and have reasonable interpretation. However, if death is the
terminating event, the recurrent event rate while the patient is alive is often of more
clinical interest, therefore we will use the conditional framework for the remainder
of the chapter.
Under the assumption that the terminating event stops future occurrences of the
recurrent event, several methods for modeling recurrent events have been proposed.
Ghosh and Lin (2000, 2002), Strawderman (2000), and Schaubel and Zhang (2010)
proposed models of the mean number of recurrent events, i.e., averaging over the
terminal event and pre-terminal event experience. Another method models the re-
current event rate conditional on “surviving” free of the terminal event (Liu et al,
2004, Ye et al, 2007). Cook and Lawless (1997) proposed several mean and rate
functions for recurrent events, conditional on the terminating event time. A detailed
report of recurrent event analysis methods generally is available from the same au-
thors (Cook and Lawless, 2007).
A popular approach under this framework has been to condition on a subject-
specific random effect associated with both the recurrent event process and the ter-
minal event, such as methods proposed by Lancaster and Intrator (1998), Wang, et
al. (2001), and Huang and Wang (2004). These frailty models have become a com-
mon method of evaluating recurrent event rates in the presence of terminal events,
and methods that explicitly model the latent frailty have been proposed by Liu et
al. (2004), Ye et al. (2007), and others. Multiple estimation methods for these
frailty models have been proposed. Given that the latent frailty is unobserved, Liu
et al. (2004) and Huang and Liu (2007) proposed to use the missing data problem
approach and use Expectation-Maximization (EM). Other estimation proposals in-
clude penalized partial likelihood (Rondeau et al., 2007)), non-parametric maximum
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likelihood (Zeng and Lin, 2009), and estimating equations (Kalbfleisch et al., 2013).
Many of these methods can estimate parameters for time-varying covariates, and
methods for estimating time-varying coefficients have also been proposed by Yu et
al. (2014).
Current methods for evaluating treatment effects in the setting of correlated re-
current and terminal events are limited to baseline treatments (Chen and Cook,
2004, Pan and Schaubel, 2009, Schaubel and Zhang, 2010). As previously described,
estimating treatment effects through traditional time-dependent methods yields in-
appropriate interpretations. Therefore, we propose the use of sequential stratification
methods (Schaubel et al, 2009) to estimate the effect of treatment assigned during
follow-up on both recurrent and terminal events.
In this chapter the methods of Chapter III are extended to the setting in which
recurrent events are stopped by correlated terminating events. As in Chapter II there
is only one treatment. However, the treatment is no longer assumed to be relatively
rare. The objective is to estimate the treatment effect on both the recurrent event
rate and the terminal event hazard in a way that respects the timing of treatment
and yields an appropriate interpretation.
The remainder of the chapter proceeds as follows. In Section 4.2 the notation and
proposed models are introduced along with the parameter estimation and asymptotic
properties. Section 4.3 provides results from simulation studies, and Section 4.4
describes an application to the A2ALL study. Finally, some concluding remarks are
offered in Section 4.5.
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4.2 Methods
4.2.1 Notation
Let Di and Ci denote terminal event and censoring times, respectively, where i
represents subject (i = 1, . . . , n) with time-dependent covariate Zi(t), which does
not include any parametric form of the event history. The observed time is given by
Xi = Di ∧ Ci where a ∧ b = min(a, b). Censoring in this setting is administrative
and depends, at most, on Zi(t). The counting process notation for the terminal
event time is given by ND∗i (t) =
∫ t
0
dND∗i (u). The terminal event is observed if
Di < Ci, i.e., N
D
i (t) =
∫ t
0
I(Ci > u) dN
D∗
i (u). Subjects begin follow-up untreated,
and after some time some subjects may be treated at time Ti. Some subjects will
experience the terminal event prior to treatment (Di < Ti), and some may never
experience treatment at all (Ti = ∞). We also define a subject-specific random
effect, γi ∼ N(0, θ), representing underlying processes that effects both the terminal
event hazard and recurrent event intensity.
We use counting process notation to set up the recurrent events as well. For
all subjects, the true number of recurrent events is given by N∗i (t) =
∫ t
0
dN∗i (u).
The number of observed events is given by Ni(t) =
∫ t
0
I(Ci > u) dN
∗
i (u), where
dN∗i (t) = I(Di > t) dN
∗
i (t), as censoring and the terminal event preclude further
recurrent events. In the following, it will be necessary to distinguish between pre-
and post-treatment recurrent and terminal events, therefore we will use
ND0i (t) =
∫ t
0
I(Ti > u) dN
D∗
i (u)(4.1)
to represent the pre-treatment terminal event for subject i and
N0i (t) =
∫ t
0
I(Ti > u) dN
∗
i (u)(4.2)
56
to represent pre-treatment recurrent events for subject i. After receiving treatment
at Ti = s, the respective quantities are
ND1i (t; s) = I(Ti = s)
∫ s+t
s
dND∗i (u)(4.3)
and
N1i (t; s) = I(Ti = s)
∫ s+t
s
dN∗i (u)(4.4)
for terminal and recurrent events, respectively. Note here that we employ the no-
tation ND1i (t; s) and N
1
i (t; s) to denote a time interval beginning at s with length
t. ND0i (t) and N
0
i (t) are similarly defined with s = 0. Since the event processes
ND1i (t;Ti) and N
1
i (t;Ti) can only begin at treatment initiation, information in [0, Ti)
is not useful for assessment of the impact of treatment on subject i.
Lastly, we define a counting process for receiving treatment, NTi (t) =
∫ t
0
I(Xi >
u) dNTi (u), which will be used for inverse weighting as described below.
4.2.2 Proposed Models
As previously noted, the comparison of interest is between the treatment and
treatment-free experience for a given subject. If this were observable in practice, the
quantities of interest would be given by the terminal event hazard
dΛ1i (t; s) = E
[
dND1i (t; s)|Zi(s), γi
]
(4.5)
and instantaneous rate function
dR1i (t; s) = E
[
dN1i (t; s)|Zi(s), γi
]
,(4.6)
where, as noted above, γi is a zero mean normal variate with variance θ and Zi(s) is
free of functions of the event history. The associated counterfactual (i.e., treatment
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free) experience can be defined as
dΛ0i (t; s) = E
[
dND0i (t; s)|Zi(s), γi
]
(4.7)
and
dR0i (t; s) = E
[
dN1i (t; s)|Zi(s), γi
]
(4.8)
for the hazard and rate functions, respectively. Note that we do not model these
quantities directly, but instead define
dΛ1i (t; s) = dΛ
0
i (t; s) exp{α?}(4.9)
and
dR1i (t; s) = dR
0
i (t; s) exp{β?}.(4.10)
Here, dΛ0i (t; s) and R
0
i (t; s) are scaled up or down by exp{α?} and exp{β?}, respec-
tively, as a result of treatment at time s.
If subject i is treated at time s we will never observe their treatment-free experi-
ence on [s, s + t), therefore we propose to use prognostic matching similar to those
described in Chapters II and III to generate a set of “similar” patients untreated at
time s. Unlike previous chapters, however, we now have both recurrent and terminal
events, and must account for each, as well as their correlation, in the prognostic
model. We propose to do so using frailty models similar to those proposed by Liu et
al (2004). In particular, we assume the following frailty models for the pre-treatment
hazard and intensity functions for terminal and recurrent events, respectively,
dΛ0i (t) = dΛ0(t) exp{δT0Zi(t) + γi}(4.11)
and
dR0i (t) = dR0(t) exp{ξT0Zi(t) + γi},(4.12)
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where we assume γi ∼ N(0, θ) as noted above. In order to make the method feasible
in larger datasets, we use a two-stage procedure to fit models (4.11) and (4.12) in
order to speed up computation time. In the first stage we estimate ξ̂ and (γ̂1, . . . , γ̂n)
using the recurrent event data only by fitting the following piecewise constant rate
model,
r0ik(t) = r
0
0k exp{ξT0Zi(tk) + γi},(4.13)
where the baseline rate parameters, r001, . . . , r
0
0K , are intended to closely approximate
dR0 from (4.12) and Zi(tk) is the potentially time-dependent covariate (excluding
any functions of the event history) taking the value associated with the beginning
of the interval (tk, tk+1]. This is essentially a piecewise Poisson regression model,
fitted by restricted pseudo-likelihood methods. This type of linearization method
uses a first order Taylor series with expansion around estimates of the best linear
unbiased predictors (BLUPS) of the subject-specific random effects. At the second
stage, model (4.11) is fitted using a Cox proportional hazards model with the γ̂i from
the first stage as an offset.
Following the model fitting procedure described above, each subject will then
have two prognostic scores, one for their pre-treatment terminal event hazard and
one for their pre-treatment recurrent event intensity. Caliper matching will be used
to match treated patients to as-yet-untreated patients based on their pre-treatment
trajectories. The distance between the treated patient i and a matched patient j will
be calculated as
ψDi,j(s) =
λ0i (s)
λ0j(s)
= exp{δT0 [Zi(s)−Zj(s)] + γˆi − γˆj}
for the terminal event hazard and
ψRi,j(s) =
dR0i (s)
dR0j (s)
= exp{ξT0 [Zi(s)−Zj(s)] + γˆi − γˆj}
59
for the recurrent event intensity.
As described in more detail below, while the prognostic model used a joint frailty
set up, the final models will estimate the treatment effect on the terminal event haz-
ard and the recurrent event intensity separately. As a result matching could proceed
in several ways. Successful matching could require that both | logψDij (s)| ≤ D and
| logψRij(s)| ≤ R for both models, where D and R are predetermined constants not
necessarily equal to each other. This would imply that the matched sets are the same
in both models. Alternatively, we could match separately for terminal and recurrent
event models, i.e. requiring | logψDij (s)| ≤ D for the former and | logψRij(s)| ≤ R for
the latter, resulting in potentially different matched sets for the two models. Some
combination of these two matching scenarios could also be applied, and different
combinations will be explored in simulation.
We can now create an indicator function that determines whether patient j is
matched to patient i, a subject treated at time s. If we use the first prognostic score
matching method described above which results in the same matched sets being used
for both models, then mij(s) = 1 indicates a successful match where
mij(s) = I(Tj = s)I(Ti > s)I(| logψDij (s)| ≤ D)I(| logψRij(s)| ≤ R).
If we want to match separately for each model, then for the terminal and recurrent
event models
mDij (s) = I(Tj = s)I(Ti > s)I(| logψDij (s)| ≤ D) = 1
and
mRij(s) = I(Tj = s)I(Ti > s)I(| logψRij(s)| ≤ R) = 1
would indicate successful matches in the respective models. As in Chapters II and III
we will again adjust for the appropriate distance measure in each model to account
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for residual differences between treated patients and matched controls. We also
adjust for the individual frailties estimated from the pre-treatment recurrent event
experience. Our final fitted models for the terminal event hazard and recurrent event
mean can then be written as
dΛ1ij(t; s) = m
D
ij (s)dΛ
0
i (t; s) exp{α?I(Ti = s) + αψ logψDij (s) + αγ γˆi}(4.14)
and
dR1ij(t; s) = m
R
ij(s) dR
0
i (t; s) exp{β? I(Ti = s) + βψ logψRij(s) + βγ γˆi},(4.15)
with associated parameter and covariate vectors
α?ψγ =

α?
αψ
αγ
 Z?Di (s) =

I(Ti = s)
log ψ̂Dij (s)
γˆi
 ,
β?ψγ =

β?
βψ
βγ
 Z?Ri (s) =

I(Ti = s)
log ψ̂Rij(s)
γˆi
 .
Models (4.14) and (4.15) can be expressed as dΛ1ij(t; s) = m
D
ij (s)dΛ
0
i (t; s) exp{α′?ψγZ?Di (s)}
and dR1ij(t; s) = m
R
ij(s) dR
0
i (t; s) exp{β′?ψγZ?Ri (s)}.
4.2.3 Parameter Estimation
In order to proceed with estimation of α? and β? we first define risk set indicators
for the two models. Let
Y Dij (t; s) = m
D
ij (s)I(Xj ∧ Ti > s+ t)
and
Y Rij (t; s) = m
R
ij(s)I(Xj ∧ Ti > s+ t)
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indicate whether patient j is included in the risk set for stratum i. Recall that both
mDij (s) and m
R
ij(s) require that patient j be untreated at time s. In addition, if
patient j is treated at s + t, they are censored from the strata in which they serve
as a control and begin their own stratum as the treated patient. Since treatment
likely depends on the recurrent event process, terminal event hazard, and the latent
frailty, this constitutes dependent censoring. We propose to use a variant of Inverse
Probability of Censoring Weighting (IPCW, Robins and Rotnitzky, 1992, Robins and
Finkelstein, 2000) to correct this problem. We will weight control subjects by the
inverse probability of treatment over the period [s, s+ t) as follows. We first model
the probability of treatment using a traditional proportional hazards model fitted
through standard partial likelihood (Cox, 1975) as
λTi (t) = λ
T
0 (t) exp{β′TZHi (t)}.
Note that this model holds under the assumption that λTi (t|H i(t)) = λTi (t|ZHi (t)),
where H i(t) = {Zi(u), ND0i (u), N0i (u), I(Ti > u), I(Xi > u); 0 ≤ u < t}, the ob-
served history for subject i on [0, t). In addition, ZHi (t) is a different covariate
vector than Zi(t) defined above, and can include the event history.
The probability of treatment on [0, t) can then be defined as
Gi(t) = exp
{
−
∫ t
0
λTi (u) du
}
.
Since we are only interested in the probability of treatment on [s, s+ t) for a given
subject we further define
Gi(t; s) =
Gi(s+ t)
Gi(s)
= exp
{
−
∫ s+t
s
λTi (u) du
}
and the associated weight functions
WDij (t; s) = Y
D
ij (t; s)Gi(t; s)
−I(Ti>s)
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and
WRij (t; s) = Y
R
ij (t; s)Gi(t; s)
−I(Ti>s)
for the terminal and recurrent events, respectively.
Using these weight functions it can be shown that:
E
[
mDij (s)W
D
ij (t; s) dM
D
ij (t; s)|Z?Di (s), γi
]
= 0
and that
E
[
mRij(s)W
R
ij (t; s) dM
R
ij (t; s)|Z?Ri (s), γi
]
= 0
where
dMDij (t; s) = Y
D
ij (s){ dNDi (s)− λij(s)}
and
dMRij (t; s) = Y
R
ij (s){ dNi(s)− dRij(s)}.
These zero mean processes can be used to set up the following sets of estimating
equations:
n∑
i=1
mDij (s)
∫ t
0
WDij (u; s) dM
D
ij (u; s),(4.16)
n∑
i=1
mDij (s)
∫ τ
0
Z?Di (s)W
D
ij (u; s) dM
D
ij (u; s),(4.17)
n∑
i=1
mRij(s)
∫ t
0
WRij (u; s) dM
R
ij (u; s),(4.18)
and
n∑
i=1
mRij(s)
∫ τ
0
Z?Ri (s)W
R
ij (u; s) dM
R
ij (u; s),(4.19)
where τ = max{X1, . . . , Xn}.
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The estimation proceeds by solving for dΛ0i (u; s) and dR
0
i (u; s) in (4.16) and (4.18)
respectively and substituting into (4.17) and (4.19). Summing across all experiments
gives final estimating equations for α?ψγ and β?ψγ,
UD(α) =
n∑
j=1
n∑
i=1
∫ τ
0
mDij (s)
∫ τ−s
0
{Z?Di (s)−Z
D
? (u; s)}ŴDij (u; s) dNDi (u; s) dNTj (s)
(4.20)
and
UR(β) =
n∑
j=1
n∑
i=1
∫ τ
0
mRij(s)
∫ τ−s
0
{Z?Ri (s)−Z
R
? (u; s)}ŴRij (u; s) dNi(u; s) dNTj (s)
(4.21)
where
ŴDij (t; s) = Y
D
ij (t; s) exp{[Λ̂Ti (s+ t)− Λ̂Ti (s)]I(Ti > s)},
ŴRij (t; s) = Y
R
ij (t; s) exp{[Λ̂Ti (s+ t)− Λ̂Ti (s)]I(Ti > s)},
Z
D
? (u; s) =
∑n
`=1 Y
D
`j (s)Ŵ
D
` (u; s)Z
?D
` (s) exp{α′?ψZ?D` (s)}∑n
`=1 Y
D
`j (s)Ŵ
D
` (u; s) exp{α′?ψZ?D` (s)}
,
and
Z
R
? (u; s) =
∑n
`=1 Y
R
`j (s)Ŵ
R
` (u; s)Z
?R
` (s) exp{β′?ψZ?R` (s)}∑n
`=1 Y
R
`j (s)Ŵ
R
` (u; s) exp{β′?ψZ?R` (s)}
.
α?ψγ and β?ψγ can then be estimated consistently by the solutions to U
D(α) = 0
and UR(β) = 0, where 0 denotes a vector with all elements equal to zero.
4.2.4 Asymptotic Properties
As described in Chapter II variance estimates for α and β are challenging to
derive in this complex setting, and asymptotic estimates may underestimate the true
variance of these parameters. One option would be to use the bootstrap, similar to
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the method described in Chapter III, however, this can be computationally intensive,
especially in the setting where there are two outcomes of interest.
We propose instead a variation of a method proposed by Lin et al (2000) to
construct confidence bands for the mean function of the proportional means model.
We first impose the following regularity conditions:
(a)
[
Ni(t), Ci(t), N
T
i (t), N
D
i (t),Zi(t), γi
]
are independent and identically distributed.
(b) P (Xi ≥ τ) > 0 for all i.
(c) Ni(τ) <∞ for all i.
(d) E[I(Ti ≤ τ)] > 0 for all i.
(e) Zi(t) is of bounded variation.
Similar to Chapter II, under these conditions it can be shown for the terminal
event that
n1/2(α̂−α) = A−1D (α)n−1/2
n∑
i=1
UDi (α) + op(1),(4.22)
where
UDi (α) =
∫ τ
0
mDi (s)
∫ τ−s
0
{Z?Di (s)− zD? (u; s)}dMDi (s)dF T (s),
AD(α) = E
[∫ τ
0
mDi (s)
∫ τ−s
0
{Z?Di (s)− zD? (u; s)}⊗2 exp{αTZ?Di dΛ0i (u; s)dF T (s)
]
,
mDi (s) is a 0/1 indicator for patient i being matched on terminal event hazard to the
index patient treated at time s and F T (s) = E[NT (s)]. Similarly, for the recurrent
event, we have
n1/2(β̂ − β) = A−1R (β)n−1/2
n∑
i=1
URi (β) + op(1),(4.23)
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where
URi (β) =
∫ τ
0
mRi (s)
∫ τ−s
0
{Z?Ri (s)− zR? (u; s)}dMRi (s)dF T (s),
AR(β) = E
[∫ τ
0
mRi (s)
∫ τ−s
0
{Z?Ri (s)− zR? (u; s)}⊗2 exp{βTZ?Ri }dR0i (u; s)dFT (s)
]
,
mRi (s) is an indicator taking value 1 when patient i is matched in terms of recurrent
event rate to the index patient treated at time s and F T (s) is defined as above.
Using this, we can estimate the distribution of (4.22) and (4.23) by repeatedly
sampling from Â−1D (α̂)n
−1/2∑n
i=1 Û
D
i (α̂)Pi for the terminal event and
Â−1R (β̂)n
−1/2∑n
i=1 Û
R
i (β̂)Pi for the recurrent event, where Pi ∼ Exp(1). Reasons
and implications for choosing the exponential distribution are discussed further in
Section 4.5.
4.3 Simulation Study
Simulation was used to assess the performance of the proposed method in mod-
erate sized samples. True values of α? and β? were determined by generating both
observed and counterfactual data for each subject. A frailty for each subject was gen-
erated from a Normal (0, 0.5) distribution, and baseline covariates Zi1 and Zi2 were
generated from a Uniform [-1,1] distribution. Pre-treatment recurrent and terminal
events were generated from the following models:
dR0i (t) = dR0(t) exp{β01Zi1 + β02Zi2 + γi}
and
dΛ0i (t) = dΛ0(t) exp{α01Zi1 + α02Zi2 + γi}.
Treatment times were then generated from
λTi (t) = λ
T
0 (t) exp{δ1Zi1 + δ2Zi2 + δ3 log(N0i (t−) + 1)}.
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For subjects with Ti < Di, post-treatment recurrent and terminal events were gen-
erated from the following intensity and hazard:
dR1i (t) = dR
1
0(t) exp{β11Zi1 + β12Zi2 + γi}
and
dΛ1i (t) = dΛ
1
0(t) exp{α11Zi1 + α12Zi2 + γi}.
Note that for each subject with Ti < Di, we generated both treatment-free and
post-treatment recurrent and terminal event experience. However, only one of these
is observed. The generated data are combined such that subject i has a recurrent
event intensity of dR0i (t) on [0, Ti) and a recurrent event intensity and terminal event
hazard of dR1i (t) and dΛ
1
i (t), respectively, on [Ti, Ti + t). For subjects with Ti > Di,
dR1i (t) and dΛ
1
i (t) are never observed, and only dR
0
i (t) and dΛ
0
i (t) are generated and
modeled for these subjects.
Once the data were generated, the hazard for treatment was modeled as λTi (t) =
λT0 (t) exp{βT1Zi1 + βT2Zi2 + βT3 log(Ni(t−) + 1)} in order to calculate weights for
IPCW. At this stage we also fit the prognostic model using the frailty model
dR0i (t) = dR0(t) exp{ξ01Zi1 + ξ02Zi2 + γi}
and
dΛ0i (t) = dΛ0(t) exp{δ01Zi1 + δ02Zi2 + γˆi}.
For the terminating event model, subjects were matched if | logψDij (s)| ≤ 0.1, and
for the recurrent event model, matching was successful if | logψRij(s)| ≤ 0.1. This
resulted in a median of 16 matches per stratum for the recurrent event model and
a median of 17 matches per stratum for the terminal event model. Parameters used
to generate are as follows: dR0 = 6, β01 = 0.3, β02 = 0.1, dΛ0 = 0.3, α01 = 0.3, α02 =
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Table 4.1: Descriptive statistics from simulations or correlated recurrent and terminal events
Scenario 1 2 3 4 5 6
% Tx 66% 66% 66% 66% 66% 66%
% Died 60% 69% 65% 53% 54% 54%
% Died Pre-Tx 87% 87% 87% 87% 87% 87%
% Died Post-Tx 46% 59% 54% 36% 39% 37%
Event Mean 11.81 10.88 12.81 10.44 11.01 11.60
0.1, λT0 = 0.25, δ1 = 0.4, δ2 = 0.2, δ3 = 0.5, β11 = 0.3, β12 = 0.1, α11 = 0.3, α12 = 0.1.
In the different scenarios dR10 took on values of 4, 4.5, 5, 6, 6.5, and 8, and dΛ
1
0 took
on values of 0.2, 0.3, 0.4, and 0.5. Each scenario generated 400 subjects and was
simulated 500 times. Standard error estimates were generated from 100 perturbations
of the weighted score residuals, and these estimates were compared to standard errors
estimated from 50 bootstrapped samples.
Descriptive information regarding proportion treated and died and average num-
ber of events is given in Table 4.1, and simulation results are given in Table 4.2. Bias
for the frailty variance, θ, was 0.020, with empirical and asymptotic standard errors
approximately equal and coverage probability close to the desired level of 0.95, indi-
cating that the prognostic model was capturing the variance in the random effects
correctly. Most scenarios showed reasonably small bias for α?, ranging in absolute
value from 0.005 to 0.028, with bias exceeding 0.02 in only one scenario. Standard
error estimates based on the proposed method were similar to empirical standard
errors, resulting in coverage probabilities ranging from 0.966-0.982. Finally, esti-
mates of β? showed relatively small amounts of bias, ranging from 0.003 to 0.017,
with coverage probabilities ranging from 0.948 to 0.972. Similar to α?, the proposed
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Table 4.2: Simulation results for correlated recurrent and terminal events using a frailty prognostic
model
Scenario Outcome α? or β? Est Bias ESE ASE CP
1 Recurrent Event −0.019 −0.016 0.003 0.055 0.059 0.964
1 Survival 0.005 −0.013 −0.018 0.212 0.235 0.980
2 Recurrent Event 0.058 0.041 −0.017 0.053 0.060 0.966
2 Survival 0.510 0.483 −0.028 0.186 0.222 0.982
3 Recurrent Event 0.267 0.262 −0.005 0.054 0.057 0.960
3 Survival 0.289 0.264 −0.025 0.194 0.228 0.982
4 Recurrent Event −0.423 −0.413 0.010 0.059 0.062 0.966
4 Survival −0.404 −0.396 0.008 0.230 0.248 0.976
5 Recurrent Event −0.305 −0.293 0.012 0.056 0.061 0.972
5 Survival −0.402 −0.388 0.014 0.225 0.248 0.966
6 Recurrent Event −0.199 −0.185 0.014 0.057 0.060 0.948
6 Survival −0.406 −0.400 0.005 0.223 0.248 0.982
ESE=empirical standard error; ASE=asymptotic standard error;
CP=coverage probability
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Figure 4.1: Histogram of parameter estimates from proposed models of correlated recurrent and
terminal events using a frailty prognostic model with normal density
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Table 4.3: Simulation results for correlated recurrent and terminal events with bootstrapped stan-
dard errors
Scenario Outcome α? or β? Est Bias ESE ASE CP
1 Recurrent Event −0.019 −0.017 0.002 0.055 0.050 0.905
1 Survival 0.005 −0.015 −0.019 0.204 0.208 0.944
2 Recurrent Event 0.058 0.042 −0.016 0.056 0.051 0.909
2 Survival 0.510 0.474 −0.036 0.188 0.191 0.942
3 Recurrent Event 0.267 0.260 −0.007 0.052 0.049 0.922
3 Survival 0.289 0.270 −0.019 0.197 0.199 0.960
4 Recurrent Event −0.423 −0.412 0.011 0.058 0.053 0.899
4 Survival −0.404 −0.401 0.002 0.231 0.224 0.940
5 Recurrent Event −0.305 −0.294 0.011 0.053 0.052 0.922
5 Survival −0.402 −0.402 0.001 0.233 0.222 0.940
6 Recurrent Event −0.199 −0.187 0.013 0.055 0.051 0.924
6 Survival −0.406 −0.397 0.008 0.233 0.225 0.950
ESE=empirical standard error; ASE=asymptotic standard error;
CP=coverage probability
method for variance estimation produced standard error estimates of β̂? which were
similar to empirical standard errors. Histograms of the estimates of α?, β?, and θ
are shown in Figure 4.1 with normal density curves, demonstrating the normality of
these estimates centered at their true value.
Table 4.3 shows simulation results when the bootstrap method is used to obtain
standard errors instead of the proposed method. This method is more computa-
tionally intensive, and gives some underestimation of the standard errors for the
recurrent event parameter, with coverage ranging from 0.899 to 0.924. The proposed
method of variance estimation, by contrast, is slightly more conservative, in some
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cases overestimating the standard errors and giving coverage probabilities slightly
over the nominal level of 0.95.
4.4 Application to Liver Transplantation
The method described above was applied to data from the Adult-to-Adult Living
Donor Liver Transplantation Cohort Study (A2ALL), supplemented with data from
the Scientific Registry of Transplant Recipients, both of which are described in Chap-
ters II and III. Patients with ESRD have increased morbidity, as shown in Chapter
II as well as increased mortality. We will use the method proposed in this chapter
to evaluate the difference in the rate of days hospitalized and hazard of mortality
between liver transplant recipients that develop ESRD post-transplant compared to
the rate and hazard that would have occurred had they not developed ESRD.
Post-LT ESRD occurred in 55 of 1447 LT recipients in A2ALL. The post-ESRD
rate of days hospitalized was 10.6 per patient year at risk compared to 4.5 days hospi-
talized per patient year at risk pre-ESRD. Of the 55 patients that developed post-LT
ESRD 23 died, while 261 deaths occurred in the 1392 patients that did not develop
post-LT ESRD. A frailty prognostic model was fitted and included donor and recipi-
ent age, recipient race, diabetes, hepatitis C diagnosis, at transplant values of creati-
nine, bilirubin, and albumin, donation after cardiac death, local, regional, or national
share, and indicators for split liver and living donor transplant. The estimated vari-
ance of the subject-specific frailty was 3.6 (SE=0.16). Matching for the final analysis
of days hospitalized rate was successful if | log ψ̂Rij(s)|<0.05, resulting in a median of
13 matches per stratum, with 2 (3.6%) strata excluded due to inability to match.
Similarly, for the mortality model, matching was successful if | log ψ̂Dij (s)|<0.15, re-
sulting in a median of 17.5 matches per stratum and 3 (5.5%) strata excluded due
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Table 4.4: Morbidity and mortality related to ESRD development post-LT: Results from proposed
method compared to traditional models
Outcome Model HR CI p-value
Recurrent Proposed Model 2.45 1.55−3.87 <0.001
Event Traditional Baseline Model 3.17 3.01−3.35 <0.001
Traditional Time-Dependent Model 1.44 1.35−1.52 <0.001
Proposed Model 1.88 1.03−3.45 0.04
Survival Traditional Baseline Model 3.52 2.23−5.56 <0.001
Traditional Time-Dependent Model 1.65 1.00−2.72 0.05
to lack of eligible matches. Two sets of traditional time-dependent (“naive”) mod-
els were also fitted, one adjusted for baseline covariates only and one adjusting for
time-dependent covariates including the event history.
Results from the three sets of models are shown in Table 4.4. Using the proposed
method, patients developing post-LT ESRD had a days hospitalized rate 2.45 times
higher than similar patients that had not developed ESRD at the time of the index
patient. This result is similar to that given in Section 2.4, although slightly lower,
indicating a slight overestimation of the effect estimate as a result of ignoring the
correlated terminal event in Chapter II. Mortality was also higher in patients devel-
oping ESRD, with an 88% higher risk of death in these patients using the proposed
method. Similar to Chapter II, we demonstrate that the traditional baseline Cox
model overestimates the effect of ESRD development on both the rate of days hos-
pitalized and the hazard of death, while the traditional time-dependent Cox model
including the event history underestimates this effect.
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4.5 Discussion
In the above chapter we propose a method for estimating effects of a time-
dependent treatment on correlated recurrent and terminal event outcomes. The
proposed method uses a frailty prognostic model to match patients that receive
treatment at time s to those that are untreated at s with similar trajectories in their
recurrent event intensity and terminal event hazards based both on covariate effects
as well as underlying frailty. The method of sequential stratification is then used to
compare the recurrent event rate and terminal event hazard between treated patients
and a matched control group representing the treated patients’ experience had they
not received treatment at time s.
The proposed method incorporates two important aspects that reduce bias when
estimating treatment effects on the recurrent event rate in the presence of a correlated
terminal event. First, it corrects bias related to the correlated terminal event by
incorporating a latent frailty into the prognostic model. We use a model similar
to that proposed by Liu et al (2004), and include the estimated frailty in the final
recurrent and terminal event models. We fit the frailty prognostic model using
estimating equations in a similar vein to methods proposed by Kalbfleisch et al
(2013). Second, we use a partly conditional model in order to correct bias related to
over and under adjustment that often occurs in traditional recurrent event models
such as those of Anderson and Gill (1982) and Lin et al (2000). In the setting where
treatment assignments are made during the course of follow-up the proposed method
conditions on the history prior to treatment and marginalizes over the history after
treatment in order to make appropriate comparisons.
In the proposed method inference depends on estimation of the asymptotic distri-
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bution of (4.22) and (4.23) via an approximation involving repeated sampling from
an exponential distribution with unit mean and variance. In the original method
proposed by Lin et al (2000) the authors simulate from a standard normal distri-
bution to approximate the asymptotic distribution of the mean function, however,
given the underestimation of standard errors by the sandwich estimator, the heavier
tails of the exponential distribution are able to correct the underestimation more
effectively than the standard normal. With the exponential distribution we end up
with slight overestimation of standard errors, therefore an in between distribution,
such as a t-distribution with 15 degrees of freedom, could be explored. The over-
coverage could also be caused by treating the estimated frailty, γi, and the weight
function as known quantities, as is done in the proposed model, however, treating
the weight function especially as a known is commonly done in the literature.
Limitations to this method include parametric assumptions on both the prognostic
model’s baseline hazard and frailty. We propose the use of a log-normal frailty,
although other distributions could by used, such as the gamma distribution which is
a common choice. Since the underlying frailty is unobserved, it may be beneficial in
some settings to assume a non-parametric form of the frailty. An additional limitation
is the proportional hazards assumption on the parameter estimates of interest, α?
and β?. This assumption can be explored using interactions with time of treatment,
s, as well as time since treatment, t as in Chapters II and III.
CHAPTER V
Conclusions and Future Work
In the above dissertation we develop methods for estimating time-dependent treat-
ment effects on the recurrent event rate using an extension of the method of sequential
stratification developed by Schaubel et al (2009). While randomized controlled trials
are the gold-standard for determining treatment effects, in many settings they are
neither feasible nor ethical. In these cases observational studies, which often include
treatment assignment after the beginning of follow-up and treatment by indication,
are necessary for estimating treatment effects. In this setting it is important to bal-
ance conditional and marginal approaches in order to obtain unbiased estimates with
appropriate interpretations.
We first presented methodology for estimating rare treatment effects on the recur-
rent event rate. We introduced a two-stage modeling technique in order to estimate
these effects. In the first stage we fit a prognostic model on the pre-treatment ex-
perience for all subjects. Treated subjects were then matched to as-yet untreated
subjects based on prognostic scores. The final model was fitted using the method of
sequential stratification yielding a treatment effect estimate which can be interpreted
as the effect of treatment on the recurrent event rate for a subject treated at time
s compared to the rate that would have occurred after s had the subject not been
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treated at that time. The use of the prognostic score for matching ensures that pa-
tients are on the same recurrent event trajectory prior to the time of treatment, but
allows these trajectories to diverge post-treatment in order to allow for a potentially
differing effect of treatment on the recurrent event rate.
In the next chapter we extended the method proposed in Chapter II in two ways.
First we allowed for multiple treatment states by introducing the concept of conven-
tional therapy, in which patients begin follow-up untreated and subsequently receive
a standard treatment. These patients are contrasted with patients that receive an
experimental treatment at time s. Second, we incorporated Inverse Probability of
Censoring Weighting in order to correct informative censoring at the time of treat-
ment. As demonstrated in Chapter II, when experimental treatment exceeds 20%,
censoring of control subjects at subsequent experimental treatment initiation induces
bias when treatment is associated with the recurrent event process.
The third method proposed addressed the case when the recurrent event process
is correlated with a terminal event. In order to account for this correlation we use
a frailty prognostic model in the first stage of modeling. Similar to the previous
two chapters the prognostic models are fit on the pre-treatment experience, however,
we propose the use of a random frailty to account for the correlation between the
recurrent and terminal events. We assume in this setting that the terminal event
is also of interest and model it in addition to the recurrent events, therefore we
complete the matching based on prognostic scores twice. The method allows for
matching to depend on prognostic scores based on the pre-treatment recurrent event
process, the pre-treatment terminal event hazard, or some combination of the two
depending on what is most appropriate for the data at hand. In addition estimated
frailty values can be incorporated into the matching. The final models give treatment
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effect estimates for both the recurrent event rate and terminal event hazard with
similar interpretation as described above, and weighting is incorporated for common
treatments.
There are several areas in which the methods proposed above could be extended.
First, in the setting of common treatments we proposed the use of the bootstrap
as well as a variation of a method proposed by Lin et al (2000). In this setting the
question of convergence of Z
?
i remains unresolved, and deserves further investigation.
One potential way to address this issue would be to extend the method in order
to allow for multiple treated subjects per stratum. In the methods proposed the
continuous time axis and matching scheme necessitates a single treated subject per
stratum, however, grouping similar treated subjects could assure convergence of Z
?
i
as well as allow for more efficient estimators of the treatment effect. Finally, another
area of interest would be to extend the current methods to allow for increments in
the recurrent event counter greater than 1, for potential application to cost data.
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